Categories
Report

(Nasdaq: GDC) Profile

OUR NEW PROFILE IS:   (NASDAQ: GDC)

____________________

GD CULTURE GROUP EXPANDS INTO LIVESTREAMING INTERACTIVE GAMES ON TIKTOK

GDC HAS BEEN SEEING A LOT OF ACTIVITY OVER THE PAST 7 DAYS

GD CULTURE GROUP UNVEILS ITS TRANSFORMATIVE AND PHOTOREALISTIC AI-DRIVEN DIGITAL HUMAN TECHNOLOGY ON TIKTOK

GD CULTURE GROUP ENTERS INTO MEMORANDUM OF UNDERSTANDING WITH PIER E MEDIA FOR EXPANSION INTO TIKTOK AGENCY BUSINESS

__________________________________________

Hello Everyone,

We have another profile for you to look at and research IMMEDIATELY.

Pull up GDC.

This is another company that we just looked at over a week ago and it went viral, touching $5.16 on record interest after a massive gap up in the morning when the company dropped breaking news.

Since then there has been a pullback after some profit taking.

We think now is a good time to research this one again.

GD Culture Group Limited (the “Company”) (Nasdaq: GDC), is a Nevada holding company currently conducting business through its subsidiaries, AI Catalysis Corp. (“AI Catalysis”). The company plans to enter into the livestreaming market with focus on e-commerce and livestreaming interactive games through its wholly owned U.S. subsidiary, AI Catalysis, a Nevada corporation incorporated in May 2023.

*****BREAKING NEWS RELEASED TODAY*****

GD CULTURE GROUP UNVEILS ITS TRANSFORMATIVE AND PHOTOREALISTIC AI-DRIVEN DIGITAL HUMAN TECHNOLOGY ON TIKTOK

NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) — GD Culture Group Limited (“GDC” or the “Company”) (Nasdaq: GDC), a Nevada holding company currently conducting business through its subsidiaries, AI Catalysis Corp. (“AI Catalysis”), today announced that it has applied cutting-edge AI-driven digital human technology (the “Technology”) to optimize its users’ experience on TikTok.

The Technology is designed to create digital humans with lifelike appearances, facial expressions, and movements seamlessly bridging the gap between reality and the digital world. The remarkably realistic appearances of the digital humans are achieved through high-quality modeling, rendering, and animation. In addition, powered by state-of-the-art natural language processing (“NLP”) and machine learning, the Technology features with strong personal traits, accurate facial animation, perfect lip synchronization, emotional expression, and speech synthesis of digital humans.

In response to the burgeoning demand within the digital landscape, AI Catalysis generates lifelike digital humans tailored for digital human live-streaming e-commerce and virtual anchors, creating innovative digital characters. In the first phase of the deployment, AI Catalysis applies the Technology to create a digital human IP matrix. A total of 30 virtual anchors have been created and are now live on TikTok. The visually appealing anchors have unique appearances, personalities, and voices, which are expected to provide value to their viewers and followers with informative, entertaining, and inspiring content. All video content creation will adhere to AI technology’s ethical standards, ensuring that the content is constructive, positive, and conveys effective information. The current enriched content covers a variety of categories, including financial and tech information, travel tips, and brand discovery. A consistent flow of short videos featuring the virtual anchors is being uploaded across 30 TikTok accounts. Virtual anchors can also represent brands and products with customized content and distinct personality. They can be seamlessly integrated with a brand’s social marketing and e-commerce strategy. This initiative aims to build and maintain a strong online presence for digital humans and accelerate AI Catalysis’s deployment for digital humans. Upon widespread deployment, digital humans will transform the business and media landscape.

AI Catalysis is also dedicated to developing, creating, and sharing generative virtual human content. Here is the 36-second video sample of a digital human developed by AI Catalysis. https://youtube.com/shorts/IWTIfsh-YfY?feature=share

These are the Company’s main business:

AI-DRIVEN DIGITAL HUMAN TECHNOLOGY

The Technology is designed to create digital humans with lifelike appearances, facial expressions, and movements seamlessly bridging the gap between reality and the digital world. Powered by state-of-the-art natural language processing (“NLP”) and machine learning, these digital humans have remarkably realistic appearances through high-quality modeling, rendering, and animation.

The company aims to provide technology application services of digital human creation and customization for social media influencers or SMBs (Small and Medium-sized Businesses) in the consumer industry, to help the clients optimize their online marketing and advertising.

LIVE-STREAMING E-COMMERCE BUSINESS

The company has introduced online e-commerce businesses on TikTok. The business focus is on capturing TikTok’s popular trend by offering carefully selected product choices with smooth delivery, aiming to redefine the online shopping experience. The company formulates a dual strategy employing both short video and live streaming to offer online shoppers a more convenient and interactive shopping experience. By growing the horizontal coverage of social media platforms and vertical user base on selected product categories, the company can create value for its customers and business partners.

LIVE STREAMING INTERACTIVE GAME

The company has launched a live-streamed game on Tiktok that offers real-time and immersive gaming experience, where viewers can actively participate as players during the livestream. The company plans to diversify its game offerings and the anchor personalities for TikTok users. It aims to serve the TikTok audience 24/7 and plans to introduce digital hosts to ensure non-stop entertainment using the digital human technology.

GD CULTURE GROUP’S PORTFOLIO COMPANY DIGITRAX RELEASES ITS PATENTED AI MUSIC PRODUCTION TOOL KR38R PRO

NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) — GD Culture Group Limited (“GDC” or the “Company”) (Nasdaq: GDC), a Nevada holding company conducting business through its subsidiaries AI Catalysis Corp. (“AI Catalysis”), today announced that its portfolio company, DigiTrax Entertainment, Inc., (“DigiTrax”), a music company at the forefront of transforming the music industry by pioneering the use of artificial intelligence (AI) solutions, has released its first AI music production software plugin tool, KR38R PRO (“Creator”). The launch heralds the release of a serious of DigiTrax’s patented AI-powered products, with a vision to leverage the technology to reshape the future of music, revolutionize music creation, and redefine music experiences.

After seven years of dedicated efforts in human-AI collaboration, KR38R PRO is built upon a total of seven DigiTrax’s patents on AI-powered music composition to provide instantaneous creative possibilities to songwriters and musicians. The Creator has been trained on music theory to fully understand the music language of songwriters and musicians. It is equipped with essential parameters such as key, chord sequences, beats per bar, and more to prompt the composition engine. KR38R PRO seamlessly integrates into existing creation workflows and is compatible with many leading digital audio workstations, including Pro Tools, Ableton, Cubase, and FL Studio.

KR38R PRO empowers musicians by streamlining the composition process while ensuring complete control over their productions. Based on its tiered subscription service, Creator makes the whole production process easier with the offering of its add-on downloadable STUDIO and SOUND PACKS featuring full session files, instruments, sounds, MIDI, and presets for Hip-Hop, EDM, Pop, and Country genres.

Mr. Xiaojian Wang, Chairman and Chief Executive Officer of the Company, commented, “We’re proud to announce the launch of DigiTrax’s latest product KR38R PRO, which showcasing our commitment to exploring new frontiers in AI-driven technologies. KR38R PRO aims to empower users in today’s highly competitive music industry by expediting their creative process. The application of this state-of-the-art technology is expected to have revolutionary impact to the industry, unleashing enormous possibilities and values for artists and labels. The launch of KR38R PRO signifies the start of a series of DigiTrax’s patented AI-empowered music technology releases. We anticipate unveiling more products in 2023 and 2024. We believe that this series of products will cater to the needs of established artists, music stakeholders and entertainment technophiles, strengthen the competitiveness of our users in the ever-evolving entertainment industry, and create substantial value for our shareholders.”

About GD Culture Group Limited

GD Culture Group Limited (the “Company”) (Nasdaq: GDC), is a Nevada holding company currently conducting business through its subsidiaries, AI Catalysis Corp. (“AI Catalysis”). The company plans to enter into the livestreaming market with focus on e-commerce and livestreaming interactive games through its wholly owned U.S. subsidiary, AI Catalysis, a Nevada corporation incorporated in May 2023. The Company’s main businesses include AI-driven digital human technology, live-streaming e-commerce business and live streaming interactive game. For more information, please visit the Company’s website at https://www.gdculturegroup.com/.

About DigiTrax Entertainment, Inc.

DigiTrax Entertainment, Inc. is a music technology company that uses artificial intelligence to develop new ways of creating and experiencing music. The company has developed a patented AI process that leverages evolutionary algorithms trained on music theory as the key innovation of the KR38R platform. The platform leverages AI for new music creation and to help artists and music labels unlock additional value from existing content. DigiTrax Entertainment, Inc. is currently participating in the NVIDIA Inception and Intel AI Partner Programs. https://digitrax.ai/

GD CULTURE GROUP ENTERS INTO MEMORANDUM OF UNDERSTANDING WITH PIER E MEDIA FOR EXPANSION INTO TIKTOK AGENCY BUSINESS

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) — GD Culture Group Limited (“GDC” or the “Company”) (Nasdaq: GDC), a Nevada holding company conducting business through its subsidiaries AI Catalysis Corp. (“AI Catalysis”), today announced the signing of a Memorandum of Understanding (the “MOU”) between AI Catalysis and Pier E Media, a leading influencer agency that connects brands with influential content creators, to expand its agency business on TikTok. The collaboration marks GDC’s strategic expansion into TikTok agency business, which is critical in boosting the Company’s performance in eCommerce and game live streaming sectors and strengthening its connections with TikTok content creators.

Pursuant to the MOU, AI Catalysis and Pier E Media shall act as the Movement directors. Additionally, Pier E Media grants the rights to AI Catalysis to utilize its agency license and TikTok accounts.

The signing of the MOU is essential to the AI Catalysis’s talent acquisition and business expansion. The partnership incorporates a system for talents recruitment and nurturing, which paves the way for building a diverse pool of talented TikTok content creators to invigorate AI Catalysis’s content creator community. Consequently, AI Catalysis is in a better position to provide a wide array of engaging content, injecting impetus to the growth of its eCommerce and game live-streaming operations.

The cooperation also aims to deepen the relationship between AI Catalysis and its creators through the offering of its specialized services. AI Catalysis is committed to catering to the needs and requirements of the creators across the board, with a comprehensive provision of services including technical support, eCommerce operation, supply chain integration, platform expertise, and monetization opportunities. In particular, AI Catalysis focuses on fostering closer connections between its creators and their audience, by empowering the content creators with AI Catalysis’s AI Digital Human avatars technology. This technology aims to enhance content personalization and quality.

Mr. Xiaojian Wang, Chairman and Chief Executive Officer of the Company, expressed his enthusiasm for the collaboration: “We are excited to announce our partnership with Pier E Media, which not only positions us as a premier TikTok agency but also underscores our commitment to nurturing stronger relationships with creators. This collaboration showcases our dedication to reshaping influencer marketing and empowering TikTok content creators. We are dedicated to providing creators with the tools they need to excel in the digital landscape.”

About Pier E Media

Pier E Media was established in 2017, and our core team consists of professionals from top domestic and international e-commerce and talent agency companies, including Douyin/TikTok. We have rich experience in talent management and channels. Pier E Media is dedicated to helping brands with integrated overseas digital platform marketing. Our team can provide end-to-end services such as account incubation, influencer collaborations, and ecommerce operations, aiming to maximize client benefits. Website: https://www.pieremedia.com/

About AI Catalysis

AI Catalysis is a leading digital marketing and AI technology company dedicated to empowering creators and influencers to excel in the digital space. With a focus on innovation and cutting-edge solutions, the company is committed to driving excellence in influencer marketing, ecommerce, and game livestreaming while nurturing stronger relationships with creators. For more information, please visit AI Catalysis’s website at: https://aicatalysis.com/.

NEWS

PUBLISHED

4 HOURS AGO

FROM DIGITAL AVATARS TO AI AGENTS: GD CULTURE GROUP TO EXPAND ITS AI FRONTIER WITH GPT-4-POWERED AI AGENT

PUBLISHED

NOV 22, 2023

GD CULTURE GROUP’S PORTFOLIO COMPANY DIGITRAX RELEASES ITS PATENTED AI MUSIC PRODUCTION TOOL KR38R PRO

PUBLISHED

NOV 21, 2023

GD CULTURE GROUP ENTERS INTO MEMORANDUM OF UNDERSTANDING WITH PIER E MEDIA FOR EXPANSION INTO TIKTOK AGENCY BUSINESS

PUBLISHED

NOV 20, 2023

GD CULTURE GROUP UNVEILS ITS TRANSFORMATIVE AND PHOTOREALISTIC AI-DRIVEN DIGITAL HUMAN TECHNOLOGY ON TIKTOK

PUBLISHED

NOV 3, 2023

GD CULTURE GROUP LIMITED ANNOUNCES CLOSING OF $10 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

PUBLISHED

NOV 1, 2023

GD CULTURE GROUP LIMITED ANNOUNCES $10 MILLION REGISTERED DIRECT PRICED AT-THE-MARKET UNDER NASDAQ RULES

PUBLISHED

SEP 5, 2023

GD CULTURE GROUP EXPANDS INTO LIVESTREAMING INTERACTIVE GAMES ON TIKTOK

PUBLISHED

AUG 28, 2023

GD CULTURE GROUP LIMITED EXPANDS GRIDS OF THE FUTURE PORTFOLIO WITH TIKTOK TO DRIVE GROWTH OF LIVE-STREAMING E-COMMERCE BUSINESS SEGMENT

PUBLISHED

AUG 21, 2023

GD CULTURE GROUP LIMITED UNVEILS REBRANDING INITIATIVES REFLECTING ITS TRANSFORMATION AND FOCUS ON GROWTH AND INNOVATION

PUBLISHED

JUN 7, 2023

GD CULTURE GROUP LIMITED PARTICIPATES AND PRESENTS AT BITBLOCK SUMMIT HELD IN NEW YORK CITY ON JUNE 1, 2023

PUBLISHED

JUN 6, 2023

GD CULTURE GROUP LIMITED ESTABLISHES SUBSIDIARY IN NEW YORK TO ADVANCE OPERATIONS AND BUSINESS GROWTH

PUBLISHED

MAY 2, 2023

GD CULTURE GROUP LIMITED ANNOUNCES DOWNSIZE OF ITS REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES AND PRIVATE PLACEMENT TO $9.55 MILLION

PUBLISHED

MAY 2, 2023

GD CULTURE GROUP LIMITED ANNOUNCES $11.55 MILLION REGISTERED DIRECT PRICED AT-THE-MARKET UNDER NASDAQ RULES AND PRIVATE PLACEMENT

MANAGEMENT TEAM

Xiaojian Wang

Chief Executive Officer, President, Chairman of the Board and Director

Mr. Wang was the Vice President of Business Development at Foregrowth Inc. in Vancouver, Canada, where he formulated and executed comprehensive business plans, achieving defined sales targets and driving market expansion, conducted training sessions for financial advisors, equipping them with in-depth knowledge of compliance requirements, market insights, and product features, and conducted extensive research and due diligence on potential alternative investment opportunities, resulting in successful acquisitions and partnerships. Prior to that, Mr. Wang was a Private Banking Consultant and an Interbank Commercial Paper Trader at China Minsheng Bank in Chongqing, China. Mr. Wang received his Bachelor of Science in Mathematics degree from University of British Columbia in 2012.

Zihao Zhao

Chief Financial Officer

Mr. Zhao was a senior audit assistant at PricewaterhouseCoopers, PWC, Shanghai from 2016 to 2019. Mr. Zhao received his Bachelor of Science in Taxation degree from Shanghai Lixin University of Accounting and Finance in 2016.

Lu Cai

Chief Operating Officer

Ms. Cai has over 10 years of extensive experience in financial management and consulting. Since July 2020, Ms. Cai has been the Chief Executive Officer of Beijing Boda Shengshi Financial Consulting Co., Ltd, a firm that offers initial public offering and pre-marketing consulting services in China. From July 2017 to May 2020, Ms. Cai was a Vice President of SINO-TONE Beijing Consulting Co., Ltd, a consulting firm based in Beijing, China. Ms. Cai graduated from Beijing Foreign Studies University.

Shuang Zhang

Vice President and Director

Ms. Zhang was appointed as the Vice President and a director of the Company, effective October 4, 2022. Ms. Zhang, co-founded Highlight Media in 2016 and has been its Chief Executive Officer since 2017. During her tenure as the Chief Executive Officer, Ms. Zhang managed the planning, creation and publication of books about the company history of industry leaders in China, published in top financial publications in China. From 2015 to 2016, Ms. Zhang was the director of public relations at Ctrip, an online travel company in China. From 2004 to 2015, Ms. Zhang was the editor-in-chief of China Business News, responsible for editing, performance, and quality control. Ms. Zhang received her bachelor’s degree in journalism from Heilongjiang University in China in 1991 and her Master of Business Administration degree from the Antai College of Management and Economics of Shanghai Jiaotong University.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY SICA MEDIA LLC FOR A ONE DAY GDC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(NYSE American: MAIA) Profile

OUR NEW PROFILE IS:  (NYSE AMERICAN: MAIA)

MAIA BIOTECHNOLOGY RECENTLY ANNOUNCES SHARE REPURCHASE PROGRAM 

MAIA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR THIO, A FIRST-IN-CLASS TELOMERE TARGETING AGENT FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER

FDA GRANTS ORPHAN DRUG DESIGNATION TO MAIA BIOTECHNOLOGY FOR THIO AS A TREATMENT FOR GLIOBLASTOMA.

     -THIS IS THE THIRD ORPHAN DRUG DESIGNATION GRANTED TO THIO, FOLLOWING THE RECEIPT OF ORPHAN DRUG DESIGNATIONS FOR HEPATOCELLULAR CARCINOMA (HCC) AND SMALL-CELL LUNG CANCER (SCLC) IN 2022. RECEIVING THREE DESIGNATIONS HIGHLIGHTS THE FDA’S RECOGNITION OF THIO’S POTENTIAL TO TREAT MULTIPLE TYPES OF CANCERS, INCLUDING RARE ONES LIKE GLIOBLASTOMA

READ THE INVESTOR PRESENTATION HERE

_______________________________________________________________________________________________________________

Hello Everyone,

We have a new NYSE profile for Tuesday’s session.

This is a company that we have profiled in the past at higher levels and it has come down over the past week after announcing an offering at significantly higher levels from it’s current price.

There could be significant room to run based on the chart if it were to see some interest and momentum.

Pull up MAIA and start your research on it tonight.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a first-in-class cancer telomere targeting agent in clinical development for the treatment of Non-Small Cell Lung Cancer (NSCLC) patients with telomerase-positive cancer cells.

FDA GRANTS ORPHAN DRUG DESIGNATION TO MAIA BIOTECHNOLOGY FOR THIO AS A TREATMENT FOR GLIOBLASTOMA

  • Third orphan drug designation (ODD) granted to THIO by the FDA; drug also holds ODDs for hepatocellular carcinoma and small cell lung cancer
  • Benefits include 7 years of U.S. market exclusivity after drug approval and tax credits for qualified clinical testing
  • Expected glioblastoma market growth from $2.2 billion to $3.2 billion globally in the next three years

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, announced today that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to its lead asset THIO, a cancer telomere-targeting agent, for the treatment of glioblastoma. This is the third orphan drug designation granted to THIO, following the receipt of orphan drug designations for hepatocellular carcinoma (HCC) and small cell lung cancer (SCLC) in 2022.

“We are pleased to receive a third orphan drug designation for THIO, further highlighting FDA’s recognition of THIO’s potential in the treatment of multiple cancer indications, including rare ones such as glioblastoma,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer. “Each year, globally, more than 300,000 people are diagnosed with brain tumors, of which, 25,000 are in the United States. Glioblastoma represents the majority of these cases in the U.S., with 15,000 new patients diagnosed and more than 10,000 deaths yearly, making it an orphan indication. Given this prevalence there is significant room for growth in the $2.2 billion glioblastoma market, which is expected to reach $3.2 billion globally in the next three years.1 We consider this ODD an important milestone for our development strategy and for glioblastoma patients who could benefit from a potentially revolutionary therapy.”

“In the data presented to the FDA, THIO successfully penetrated the blood brain barrier (BBB) in syngeneic and humanized mouse models of telomerase-expressing brain cancers. Treatment with THIO resulted in potent anticancer activity and significant expansion of the animal lifespan for several difficult to treat cell lines and xenograft mouse models,” added Sergei Gryaznov, Ph.D., MAIA’s Chief Scientific Officer. “These results stem from THIO’s remarkable mechanism of action and its BBB penetrating property that allows for direct targeting of brain tumors in vivo and potentially in glioblastoma patients.”

“Glioblastoma is the most aggressive and most common type of cancer that originates in the brain. With very limited treatment options available, glioblastoma patients have exceptionally short survival durations, and only 7% remain alive five years after being diagnosed with the condition,”2 said Mihail Obrocea, MD, MAIA’s Chief Medical Officer. “We are optimistic about our telomere-targeting agent’s ability to provide clinical benefit in patients with glioblastoma, and we look forward to studying THIO for the treatment of this highly unmet medical indication in a future trial.”

Enrollment is ongoing in a Phase 2 trial of THIO, THIO-101, evaluating the drug candidate in patients with advanced non-small cell lung cancer (NSCLC). THIO is the only direct telomere targeting agent currently in clinical development.

About Orphan Drug Designation

The FDA’s Orphan Drug Act of 1983 was designed to incentivize the development of therapies that demonstrate promise for the treatment of rare (orphan) diseases or conditions. A disease is classified as “rare” if it affects fewer than 200,000 people total in the U.S., or if the cost of developing a drug and making it available in the U.S. for such diseases will exceed any potential profits from its sale due to the small target population size. The FDA’s ODD program provides multiple incentives to make orphan drug development more financially possible for companies to pursue, such as up to seven years of market exclusivity for the approved orphan drug, up to 20 years of 25% federal tax credit for expenses incurred in conducting clinical research within the U.S. and waiver of Prescription Drug User Fee Act (PDUFA) fees for orphan drugs, a value of approximately $2.9 million in 2021.

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101, a Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate THIO’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of THIO administered prior to an anti-PD1 agent will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of THIO administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of THIO using Overall Response Rate (ORR) as the primary clinical endpoint. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

MAIA BIOTECHNOLOGY REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT DEVELOPMENT PROGRESS FOR ANTICANCER ASSET THIO

  • Substantial THIO program progress including unprecedented disease control rate (DCR) of 100% in second-line non-small cell lung cancer (NSCLC)
  • Key THIO findings in gliomas, pediatric brain cancer, and second generation THIO-derived cancer therapies
  • Strong pace of enrollment in THIO-101 Phase 2 trial exceeds average enrollment pace in similar NSCLC trials

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, today reported financial results for the third quarter ended September 30, 2023 and key operational updates.

“Our successful and productive third quarter was punctuated by the outstanding data on our lead asset THIO that we recently revealed, and an accelerating pace of enrollment in our THIO-101 Phase 2 trial,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer. “We are expanding our trial in Europe, and with the FDA’s recent clearance for THIO studies in the U.S. as part of THIO-101, we have reached an essential milestone in the clinical development of THIO. Preliminary efficacy data from the trial is excellent and includes an unprecedented disease control rate (DCR) of 100% in second-line NSCLC treatment, far surpassing the standard of care DCR of 53-64%. We achieved the pre-determined statistical requirements to proceed to the next stage of the trial earlier than expected, and we look forward to sharing our continuing progress in the coming months and into 2024.”

Third Quarter Business Highlights and Recent Developments

THIO Program

Announced 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data: 100% preliminary DCR was observed in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatment. DCRs across all dose levels met the pre-determined statistical requirements earlier than expected to proceed to next stage of the THIO-101 Phase 2 trial.

Highly Potent Anticancer Activity in Gliomas: MAIA’slead asset THIO showed highly potent anticancer activity in models of glioma, an aggressive type of brain tumor that originates from glial cells and is among the most difficult-to-treat cancers. As a monotherapy, THIO demonstrated efficacy in multiple glioma cell lines that had acquired resistance to the current state-of-the-art care temozolomide (TMZ).

THIO as Potential Therapy for Pediatric Brain Cancer: Study data showed THIO’s potent anticancer activity in diffuse intrinsic pontine glioma (DIPG), one of the most aggressive tumors affecting the central nervous system in children. The treatment resulted in noticeably increased tumor sensitivity to immune or ionizing radiation therapies.

Higher Anticancer Potency of Next Generation THIO Conjugates: Positive Investigational New Drug-enabling study data on telomere-targeting agents derived from lipid-modified THIO molecules warrant further in vivo in-depth investigation of THIO-like agents as second generation cancer therapies.

THIO-101 Phase 2 Clinical Trial

U.S. FDA Clearance of THIO IND Application: TheU.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application enabling THIO to be evaluated in the U.S. as part of THIO-101, the Company’s ongoing global phase 2 clinical study in patients with advanced non-small cell lung cancer (NSCLC). THIO is being tested in sequential combination with a checkpoint inhibitor (CPI) to evaluate anti-tumor activity and immune response in NSCLC patients.

Strong Pace of Enrollment in THIO-101: 49 patients have been dosed to date at a pace of enrollment that is currently exceeding the average enrollment pace in similar NSCLC trials. Out of the 49 patients dosed, 37 have already completed at least one post baseline assessment.

Continuing Positive Preliminary Survival Data: The first 2 subjects dosed on trial (both receiving 3rd line of treatment) reported long term survival of 14.6 and 12.5 months, respectively, at the latest post baseline assessment with no new anti-cancer treatment initiated. Follow up was ongoing for the first subject at the time of data cut-off.

Third Quarter 2023 Financial Results

Cash Position: Cash totaled approximately $6.1 million as of September 30, 2023, compared to $10.9 million in cash as of December 31, 2022.

Research and Development (R&D) Expenses: R&D expenses were approximately $2.6 million for the quarter ended September 30, 2023, compared to approximately $2.3 million for quarter ended September 30, 2022. The increase was primarily related to an increase in scientific research expenses.

General and Administrative (G&A) Expenses: G&A expenses were approximately $2.4 million for the quarter ended September 30, 2023, compared to approximately $1.7 million for the quarter ended September 30, 2022. The increase for the quarter was primarily related to an increase in professional fees related to the write-off of deferred offering costs and an increase in investor relations costs.

Other Income, Net: Other income was approximately $0.08 million for the quarter ended September 30, 2023, compared to other income, net of $0.19 million for the quarter ended September 30, 2022, primarily related to a change in the fair value of warrant liability.

Net Loss: Net loss was approximately $4.9 million, or $0.36 per share, for the quarter ended September 30, 2023, as compared to net loss of approximately $4.9 million, or $0.48 per share, for the quarter ended September 30, 2022. Weighted average shares outstanding were 13,675,802 in the third quarter of 2023, compared to 10,165,622 in the third quarter of 2022.

For additional information on the Company’s financial results for the quarter ended September 30, 2023, please refer to the Form 10-Q filed with the SEC.

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101, Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate THIO’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of THIO administered prior to an anti-PD-1 agent will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of THIO administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of THIO using Overall Response Rate (ORR) as the primary clinical endpoint. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

MAIA BIOTECHNOLOGY REVEALS NEW DATA SHOWING THIO’S POTENT ANTICANCER ACTIVITY IN AGGRESSIVE PEDIATRIC BRAIN CANCER

OCT 12, 2023 9:20AM EDT

Treatment demonstrates decreased cancer cell proliferation and increased tumor sensitivity to ionizing radiation

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, announced that study data shows THIO’s potent anticancer activity in Diffuse Intrinsic Pontine Glioma (DIPG), one of the most aggressive tumors affecting the central nervous system in children.

The data was recently presented at the Society for Neuro-Oncology’s 2023 Pediatric Neuro-Oncology Research Conference and published in the Neuro-Oncology journal (Volume 25, Issue Supplement_1, June 2023, Page i13). The study evaluated THIO as a potential treatment for DIPG based on inducing direct telomeric DNA damage mediated cancer cell death and activating antitumor immunity in DIPG through the intracellular cGAS/STING pathway, which resulted in noticeably increased tumor sensitivity to immune or ionizing radiation therapies.

Radiotherapy is the only standard of care treatment option for DIPG, yet it is rarely curative. In recent years, several immunotherapy strategies have emerged as potential treatments for DIPG. However, the low mutational burden and rare infiltration of T lymphocytes renders these tumors immunologically “cold” and, therefore, poses challenges for general immunotherapy.

“We have shown that THIO treatment sensitized DIPG cells to ionizing radiation (IR), leading to a significant decrease in DIPG cell proliferation in vitro and in vivo models,” said MAIA’s Chief Scientific Officer Sergei Gryaznov, Ph.D. “These encouraging preclinical studies may support further potential preclinical and clinical development of THIO to be used in combination with IR to treat children with high-risk pediatric brain tumors.”

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer(NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

MAIA BIOTECHNOLOGY ANNOUNCES SHARE REPURCHASE PROGRAM

September 28, 2023 8:01am EDT

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $800,000 of its Class A common stock through September 2024.

“This share repurchase program demonstrates the confidence we have in our market opportunity and our strategy to invest for long-term growth, which we believe is not reflected in the current market valuation,” said Vlad Vitoc, MAIA’s Chief Executive Officer. “By establishing a repurchase plan, we add another tool to our arsenal that can assist with our future financing efforts, enable us to unlock more of the long-term opportunity we see ahead, and drive sustainable value for all stakeholders.”

With a share repurchase program, MAIA may repurchase shares from time to time through various methods, including in open market transactions, in privately negotiated transactions or otherwise, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, in compliance with applicable state and federal securities laws. The timing, as well as the number and value of shares repurchased under the program, will be determined by the Company at its discretion and will depend on a variety of factors, including our assessment of the intrinsic value of the Company’s common stock, the market price of the Company’s common stock, general market and economic conditions, available liquidity, compliance with the Company’s debt and other agreements, applicable legal requirements, the nature of other investment opportunities available to the Company, and other considerations. The Company is not obligated to purchase any shares under the repurchase program, and the program may be suspended, modified, or discontinued at any time without prior notice. The Company expects to fund the repurchases by using cash on hand and expected free cash flow to be generated in the future.

Significant Market Opportunity

  • Cancer is the most dominant of the age-related disease categories and has life altering impacts in the lives of patients and their close ones
  • The number oF people aged 80 years or older is expectedtotriplebetween 2020 and 2050 to reach 426 million
  • Approximately40%ofpeoplealivetodayareprojectedtobediagnosed with a cancer type in their lifetime, and 20% will die of it
  • NSCLC is the leading tumor type: Mortality 1.7M / Sales $32B (2022)
  • CRCissecond:Mortality1M/Sales$20B(2022)

Clinical Programs

THIO-101: Ph 2 trial THIO + LIBTAYO® (cemiplimab) – enrolling (35 patients dosed to date)

  • Go-to-market trial in second line NSCLC
  • Objectives: select most efficacious dose and expand into pivotal trial
  • Started in 2022 in Australia & Europe; to include US in 2023
  • Regeneron clinical supply agreement for Libtayo®
  • File for accelerated approval in 2025
  • Part A (Safety Lead-in) Complete: No dose-limiting toxicities (DLTs), No Serious Adverse Events (SAE) or Serious Unexpected Suspected Adverse Reactions (SUSAR); Safety profile substantially better than current Standard of Care (SoC)
  • Preliminary Survival: first 2 patients dosed in Part A continue to be alive, 12.2 and 11.5 months from treatment initiation; progression free after last dose, 10.2 and 8.5 months respectively, with no new treatment; in real-world clinical practice, observed survival in similar heavily pretreated patients is 3-4 months; weeks without therapy
  • Disease Control Rate: 82%; subjects with 1+ post-baseline response assessment (n=11, 06/23/23); DCR for SoC in third line: 25-35%
  • Part B (efficacy/dose selection) initiated THIO-102: Ph 2 trial THIO + CPIs
  • Go-to-market trial in late line of therapy in multiple tumor. types: Colorectal Cancer (CRC), Hepatocellular Carcinoma (HCC, 90% of primary type of liver cancers), and Solid Tumors of any type (ST)
  • 3 umbrellas in each: THIO + Libtayo (REGN); Keytruda (MRK); Tecentriq (Genentech/Roche)
  • Objectives: select most efficacious combination by tumor type and expand into pivotal trials (9+ possible market entry indications)
  • Start in 2023, to include US, Europe, Asia, etc.
  • File for accelerated approvals in 2026 and beyond THIO-103: Ph 2/3 trial of THIO + CPIs
  • First line NSCLC and SCLC
  • Expand to Breast, Prostate, Pancreatic, Ovarian, Gastric Cancer, etc.

THIO is a Unique Direct Telomere Targeting Agent
• Potential to be used in combination with other anticancer and immune therapies
• Dual, novel mechanism of action: telomere

targeting + immunogenic
• FDA awarded THIO 2 Orphan Drug

Designations: HCC and SCLC!
• Excellent efficacy: achieved complete and durable responses in HCC in vivo models (peer-reviewed published study)

MAIA BIOTECHNOLOGY ANNOUNCES POTENT ANTICANCER ACTIVITY OF THIO IN GLIOMAS

October 10, 2023 8:01 am EDT   CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that its lead asset THIO showed highly potent anticancer activity in gliomas, an aggressive type of brain tumor that originates from glial cells. THIO’s novel dual mechanism of action – direct telomere targeting and immune system activation, has previously demonstrated similar efficacy in multiple types of telomerase-active tumors.

THIO was evaluated in various in vitro and in vivo models of gliomas. The results demonstrate the promising therapeutic role of THIO for the treatment of primary and temozolomide-resistant recurrent gliomas through specific telomerase-mediated induction of telomeric DNA damage in glioma cells

“High grade adult gliomas are among the most difficult-to-treat cancers, with less-than-desirable clinical outcomes. These encouraging results further highlight THIO’s excellent anti-cancer activity across several cancer indications,” said Vlad Vitoc, M.D., MAIA’s Chief Executive Officer. “We look forward to evaluate THIO as a treatment for brain cancer in clinical setting.”

“THIO was effective in the majority of human and mouse glioma cell lines with no apparent toxicity against normal astrocytes. As a monotherapy, THIO demonstrated efficacy in multiple glioma cell lines that had acquired resistance to the current state-of-the art care temozolomide (TMZ). THIO induced apoptosis in several human glioma cell lines that grow as three-dimensional tumor mass-mimicking neurospheres,” said MAIA’s Chief Scientific Officer Sergei Gryaznov, Ph.D. “Additionally, THIO produced telomeric DNA damage responses not only in glioma cell lines, but also in diverse human-derived tumor specimens (PDXs). In vivo, THIO significantly decreased tumor proliferation in glioblastoma xenografts and a PDX model of glioblastoma.”

The reviewed results were published in: Clin Cancer Res (2021) 27 (24): 6800–6814.

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

Partnership with Regeneron

• Clinical supply agreement: Regeneron provides Libtayo® for THIO-101

• Equivalent to $32M non-dilutive participation (largest financing move to date)

• Potentially expand existing relationship and target new companies

Strong and Growing IP Portfolio

• Potential for receiving NCE marketing exclusivity; 5 patents issued, 12 patent applications pending

Next Generation Potential Telomere Targeting Therapeutics
• 84 new molecules engineered in last 12

months; Same mechanism of action as THIO • MAIA-2021-020, MAIA-2022-012 and

MAIA-2021-029 significantly moreCefficacious
• Follow THIO to commercial stage within 4-5 years

NEWS

PUBLISHED

NOV 17, 2023

MAIA BIOTECHNOLOGY (NYSE: MAIA) HAS RECEIVED FDA ORPHAN DRUG DESIGNATION FOR THIO AS A TREATMENT FOR MOST AGGRESSIVE BRAIN CANCER

PUBLISHED

NOV 15, 2023

MAIA BIOTECHNOLOGY ANNOUNCES $4 MILLION REGISTERED DIRECT OFFERING

Nov 10, 2023 7:01am EST

FDA GRANTS ORPHAN DRUG DESIGNATION TO MAIA BIOTECHNOLOGY FOR THIO AS A TREATMENT FOR GLIOBLASTOMA

Nov 07, 2023 8:15am EST

MAIA BIOTECHNOLOGY REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT DEVELOPMENT PROGRESS FOR ANTICANCER ASSET THIO

Oct 30, 2023 8:41am EDT

MAIA BIOTECHNOLOGY REVEALS HIGHER ANTICANCER POTENCY OF TELOMERE-TARGETING COMPOUNDS DERIVED FROM THIO

Oct 24, 2023 8:00am EDT

MAIA BIOTECHNOLOGY ANNOUNCES 100% DISEASE CONTROL IN SECOND-LINE NON-SMALL CELL LUNG CANCER DEMONSTRATING IMPRESSIVE POSITIVE PRELIMINARY EFFICACY DATA FOR ONGOING THIO-101 PHASE 2 TRIAL

Oct 19, 2023 8:35am EDT

MAIA BIOTECHNOLOGY TO PRESENT PRELIMINARY SAFETY AND EFFICACY DATA FROM THIO-101 PHASE 2 CLINICAL TRIAL AT EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS 2023

Oct 17, 2023 8:01am EDT

MAIA BIOTECHNOLOGY TO PRESENT LATEST FINDINGS FOR SECOND GENERATION THIO PROGRAM AT TURKISH BIOCHEMICAL SOCIETY’S INTERNATIONAL BIOCHEMISTRY CONGRESS 2023

Oct 12, 2023 9:20am EDT

MAIA BIOTECHNOLOGY REVEALS NEW DATA SHOWING THIO’S POTENT ANTICANCER ACTIVITY IN AGGRESSIVE PEDIATRIC BRAIN CANCER

Oct 10, 2023 11:15am EDT

MAIA BIOTECHNOLOGY ACCELERATES ENROLLMENT IN THIO-101 PHASE II CLINICAL TRIAL AS EFFICACY IS OBSERVED IN DOSED PATIENTS

Oct 10, 2023 8:01am EDT

MAIA BIOTECHNOLOGY ANNOUNCES POTENT ANTICANCER ACTIVITY OF THIO IN GLIOMAS

Oct 03, 2023 8:01am EDT

MAIA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR THIO, A FIRST-IN-CLASS TELOMERE TARGETING AGENT FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER

Sep 28, 2023 8:01am EDT

MAIA BIOTECHNOLOGY ANNOUNCES SHARE REPURCHASE PROGRAM

Aug 08, 2023 8:00am EDT

MAIA BIOTECHNOLOGY REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES UPDATES FOR THIO-101 PHASE 2 TRIAL FOR NON-SMALL CELL LUNG CANCER

Jul 11, 2023 8:00am EDT

MAIA BIOTECHNOLOGY REPORTS UPDATES ON DISEASE CONTROL RATES FOR THIO-101 PHASE 2 TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER

Jul 10, 2023 8:00am EDT

MAIA BIOTECHNOLOGY REPORTS UPDATES ON PRELIMINARY SURVIVAL DATA FOR THIO-101 PHASE 2 TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER

Jun 20, 2023 8:00am EDT

MAIA BIOTECHNOLOGY ANNOUNCES UPDATES IN ENROLLMENT IN PHASE II CLINICAL TRIAL: THIO-101 HAS ENROLLED 29 PATIENTS

Jun 07, 2023 8:00am EDT

MAIA BIOTECHNOLOGY FILES SECOND PATENT FOR NEW TELOMERE-TARGETING MOLECULES PROGRAM

May 08, 2023 8:00am EDT

MAIA BIOTECHNOLOGY REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Apr 27, 2023 4:10pm EDT

MAIA BIOTECHNOLOGY, INC. ANNOUNCES CLOSING OF PUBLIC OFFERING

Apr 24, 2023 9:06pm EDT

MAIA BIOTECHNOLOGY, INC. ANNOUNCES PRICING OF PUBLIC OFFERING

Apr 20, 2023 8:00am EDT

MAIA BIOTECHNOLOGY REPORTS PRELIMINARY SURVIVAL DATA IN PART A OF THIO-101 PHASE 2 TRIAL FOR NON-SMALL CELL LUNG CANCER

MANAGEMENT TEAM

team

VLAD VITOC, MD, MBA

CHIEF EXECUTIVE OFFICER AND CHAIRMAN

Dr. Vitoc is our Chairman of Board, Chief Executive Officer, and President. Dr. Vitoc has a broad array of experience across commercial strategic analysis and planning and medical affairs, in which he has 20 years of experience. During that time, Dr. Vitoc has managed and supported over 20 early, launch, and mature stage compounds, which have included targeted therapies and immune therapies across more than 25 tumor types, including colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer, prostate cancer, and renal cell carcinoma. Vlad received an M.D. from the University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania, and his M.B.A. from the University of South Carolina.

team

JOSEPH F. MCGUIRE

CHIEF FINANCIAL OFFICER

Mr. McGuire is our Chief Financial Officer, and he brings over 30 years of experience to MAIA, having served as Chief Financial Officer for several privately held and publicly traded companies in the healt

team

SERGEI M. GRYAZNOV, PHD

CHIEF SCIENTIFIC OFFICER

Dr. Gryaznov is our Chief Scientific Officer. Dr. Gryaznov is an internationally recognized scientist and expert in the areas of modern drug discovery and development, oncology, telomerase, immune-regulatory therapeutics, nucleosides, nucleotides, DNA and RNA analogues, lipid and other conjugates, small molecules, and nucleic acid based therapeutic agents. Dr. Gryaznov is the co-inventor of a novel telomere-by-telomerase-targeting therapeutic approach to potential cancer treatment and responsible for leading the research team that characterized THIO’s telomere targeting activity, our lead compound in development. Dr. Gryaznov obtained an M.S., with Honors, in Organic Chemistry and a Ph.D. in Chemistry of Natural Products from M.V. Lomonosov Moscow State University. Dr. Gryaznov also completed a post-doctoral fellowship program in Chemistry at Northwestern University in Evanston, IL.

team

MIHAIL OBROCEA, MD

CHIEF MEDICAL OFFICER

Mihail is a board-certified internist and hematologist/oncologist with over 25 years’ experience in drug development in both academia and pharmaceutical/biotechnology industry. His broad clinical drug development expertise in both hematology and oncology covers equally early and late-stage development of cell therapy, cancer vaccines, monoclonal antibodies, and small molecules. Mihail completed a residency program in internal medicine at Yale University followed by a fellowship program in hematology/oncology at Dartmouth with academic appointment as Instructor of Medicine in the division of Hematology & Oncology at Mary Hitchcock Medical Center and Geisel Medical School at Dartmouth.

He started his career in pharmaceutical industry at Pfizer Oncology leading the CD40 agonist and IGF-1R antibodies projects, which entered in early clinical trials. Subsequently he led the Medical Affairs Oncology group at MedImmune, Gaithersburg MD and later as VP, Clinical Development Oncology at MannKind Corp., Valencia, CA successfully brought into clinic two cancer vaccine programs. As a Global Project Lead for AbbVie Biotherapeutics in Redwood City, CA, he was responsible for the early clinical oncology monoclonal antibody programs and as Head, Medical Sciences at Pharmacyclics, Sunnyvale CA he took part in the commercial launch of ibrutinib (IMBRUVICA™) program in mantle cell lymphoma and chronic lymphocytic leukemia. As VP of Clinical and Medical Affairs at SFJ Pharmaceutical Group, a venture pharma company supported the medical and business operations of the Pfizer Oncology partnership on the Phase 3, pivotal trial which led to the FDA approval of Besponsa® (inotuzumab ozogamicin) in the R/R adult B-cell ALL.

Later as US Clinical Lead at Nanobiotix Corp, a biotechnology company based in Paris, France which develops nanotechnologies for use in radiation oncology, established the US clinical programs and was involved in the strategic business development, investor, and partner interaction. As a Program Lead at Juno Therapeutics Inc and later Celgene he had the US clinical oversight of 2 clinical trials including the registration Ph 3 trial in second line aggressive large B-cell lymphomas of BREYANZI® (lisocabtagene maralucel) an autologous CD19 targeted CAR T program approved in both US and EU in R/R large B-cell lymphoma. More recently, as Project and Clinical Lead at Atara Bio, a T-cell therapy company based in Thousand Oaks, CA he supported the pre-clinical and clinical development of the Atara’s allogeneic CAR T platform for both lymphoma and solid tumor indications.

Mihail published in oncology peer-reviewed literature and is co-author of a couple of books related to cancer vaccines and immunology as well as he holds several patents in the field of biotechnology.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY SICA MEDIA LLC FOR A ONE DAY MAIA AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(NASDAQ: SOPA) Profile

No alt text provided for this image

OUR NEW PROFILE IS:   (NASDAQ: SOPA)

WITH CASH ON HAND OF $8.2 MILLION (APPROXIMATELY $0.26 PER SHARE) AND BOOK VALUE OF $9.9 MILLION(APPROXIMATELY $0.32 PER SHARE) AS OF 30 SEPTEMBER 2023, SOPA IS WELL CAPITALISED FOR CONTINUING ACQUISITIONS OF SEA COMPANIES IN ITS DIGITAL ADVERTISING, TRAVEL, LIFESTYLE, TELECOMMUNICATIONS, AND LOYALTY/FINTECH VERTICALS FOR THE REST OF 2023 AND 2024

SOPA JUST ANNOUNCEED THAT REVENUES INCREASED 117% YOY; GROSS PROFIT MARGIN IMPROVED TO 28.1%; CASH OPERATING EXPENSES DECLINED 32.6% YOY

SOPA’S PORTFOLIO OF COMPANIES BOASTS MORE THAN 3.3 MILLION REGISTERED USERS AND OVER 205,000 REGISTERED MERCHANTS

SOCIETY PASS INC. (NASDAQ: SOPA) ANNOUNCES PLANS TO SPINOUT TWO PROFITABLE BUSINESS UNITS INTO NEW PUBLICLY-TRADED COMPANIES VIA NASDAQ IPOS IN 2024

      _________________

Hello Everyone,

We have another Nasdaq that is sitting under .50 right now that we want to bring to your attention.

Pull up SOPA immediately.

SOPA is a data-driven ecosystem that was founded in 2018. It focuses on loyalty, fintech, and e-commerce in the rapidly growing markets of Vietnam, Indonesia, Philippines, Singapore, and Thailand. These countries account for more than 80% of the population in Southeast Asia. SoPa operates six interconnected verticals, including loyalty, digital media, travel, telecoms, lifestyle, and F&B, and has offices in Los Angeles, Bangkok, Ho Chi Minh City, Jakarta, Manila, and Singapore. It seamlessly connects millions of registered consumers and hundreds of thousands of registered merchants and brands across multiple product and service categories throughout Southeast Asia, with a critical focus on acquisitions.

SOPA is an acquisition-focused holding company operating 5 interconnected verticals (loyalty, digital media, travel, telecoms, and lifestyle), which seamlessly connects millions of registered consumers and hundreds of thousands of registered merchants/brands across multiple product and service categories throughout SEA.

Society Pass completed an initial public offering and began trading on the Nasdaq under the ticker SOPA in November 2021.SoPa acquires fast growing e-commerce companies and expands its user base across a robust product and service ecosystem. SoPa integrates these complementary businesses through its signature Society Pass fintech platform and circulation of its universal loyalty points or Society Points, which has entered beta testing and is expected to launch broadly at the beginning of 2023. Society Pass loyalty program members earn and redeem Society Points and receive personalised promotions based on SoPa’s data capabilities and understanding of consumer shopping behaviour. SoPa has amassed more than 3.7 million registered consumers and over 650,000 registered merchants and brands. It has invested 2+ years building proprietary IT architecture to effectively scale and support its consumers, merchants, and acquisitions.

Society Pass leverages technology to tailor a more personalised experience for customers in the purchase journey and to transform the entire retail value chain in SEA. SoPa operates Thoughtful Media Group, a Thailand-based, a social commerce-focused, premium digital video multi-platform network; NusaTrip, a leading Indonesia-based Online Travel Agency; VLeisure, Vietnam’s leading provider of hotel management and payment solutions; Gorilla Global, a Singapore-based, mobile network operator; Leflair.com, Vietnam’s leading lifestyle e-commerce platform.

Society Pass Inc’s (Nasdaq: SOPA) 9 Mths 2023 Financials : Revenues Increased 117% yoy; Gross Profit Margin Improved to 28.1%; Cash Operating Expenses Declined 32.6% yoy

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) — Society Pass Incorporated (Nasdaq: SOPA) (“SoPa”), Southeast Asia (SEA)’s next generation, data-driven, loyalty, fintech and e-commerce ecosystem, today announces unaudited financial results for third quarter ended 30 September 2023and a filing of its 3Q 2023 Form 10-Q with the Securities and Exchange Commission (SEC).

Click Here (on SEC website) to view 3Q 2023 Form 10-Q filing.

Summary Points:

• With cash on hand of $8.2 million (approximately $0.26 per share) and book value of $9.9 million(approximately $0.32 per share) as of 30 September 2023, SoPa is well capitalised for continuing acquisitions of SEA companies in its digital advertising, travel, lifestyle, telecommunications, and loyalty/fintech verticals for the rest of 2023 and 2024.

• 9 months 2023 revenues grew 117.0% year on year (from $2,994,416 in 9 months 2022 to $6,498,878in 9 months 2023).

• 3Q 2023 revenues grew 10.7% year on year (from $2,050,264 in 3Q 2022 to $2,269,066 in 3Q 2023).

• 3Q 2023 revenues grew 3.7% quarter on quarter (from $2,187,232 in 2Q 2023 to $2,269,066 in 3Q 2023).

• 9 months 2023 gross profit grew 523.2% year on year (from $293,004 in 9 months 2022 to $1,825,960 in 9 months 2023).

• 3Q 2023 gross profit grew 82.7% year on year (from $307,935 in 3Q 2022 to $562,564 in 3Q 2023).

• 3Q 2023 gross profit declined 2.5% quarter on quarter (from $577,159 in 2Q 2023 to $562,564 in 3Q 2023).

• 9 months 2023 gross profit margin grew to 28.1% in 9 months 2023 from 9.8% in 9 months 2022.

• 3Q 2023 gross profit margin grew to 24.8% in 3Q 2023 from 15.0% in 3Q 2022.

• 3Q 2023 gross profit margin declined to 24.8% in 3Q 2023 from 26.4% in 2Q 2023.

• While 9 months 2023 revenues grew 117.0% year on year, 9-month 2023 cash operating expenses declined 32.6% year on year (from $15,275,821 in 9 months 2022 to $10,295,103 in 9 months 2023).

• While 3Q 2023 revenues grew 10.7% year on year, 3Q 2023 cash operating expenses declined 54.6% year on year (from $7,426,684 in 3Q 2022 to $3,368,443 in 3Q 2023).

• While 3Q 2023 revenues grew 3.7% quarter on quarter, 3Q 2023 cash operating expenses increased 15.1% quarter on quarter (from $2,927,505 in 2Q 2023 to $3,368,443 in 3Q 2023).

• 9 months 2023 digital advertising revenues represent 70.5% of total revenues and grew 278.0% year on year from ($1,211,428 in 9 months 2022 to $4,579,429 in 9 months 2023).

• 3Q 2023 digital advertising revenues represent 78.7% of total revenues and grew 47.3% year on year from ($1,211,428 in 3Q 2022 to $1,784,695 in 3Q 2023).

• 3Q 2023 digital advertising revenues represent 78.7% of total revenues and grew 18.1% quarter on quarter from ($1,510,960 in 2Q 2023 to $1,784,695 in 3Q 2023).

• 9 months 2023 travel revenues represent 22.1% of total revenues and grew 704.2% year on year from ($178,206 in 9 months 2022 to $1,433,133 in 9 months 2023).

• 3Q 2023 travel revenues represent 17.2% of total revenues and grew 119.1% year on year from ($178,206 in 3Q 2022 to $390,384 in 3Q 2023).

• 3Q 2023 travel revenues represent 17.2% of total revenues and declined 29.8% quarter on quarter from ($556,042 in 2Q 2023 to $390,384 in 3Q 2023).

• Since inception, SoPa has onboarded approximately 3.7 million registered consumers, approximately 650,000 registered merchants/brands and approximately 10,000 influencers onto its ever-expanding next generation digital ecosystem and loyalty platform in SEA.

• SoPa operates five verticals in SEA: digital advertising, travel, lifestyle, fintech/loyalty, and telecoms.

• SoPa operates in five SEA countries: Singapore, Vietnam, Indonesia, Philippines and Thailand.

• SoPa employs approximately +200 people throughout SEA.

Raynauld Liang, Society Pass Inc Chief Executive Officer, explains, “Our compelling revenue growth and dramatic profit margin expansion, as evidenced in the Company’s 9 months 2023 financial performance, substantiate our acquisitions-focused business plan to build the next generation digital ecosystem and fintech loyalty platform here in SEA. Despite 9 months 2023 revenues growing 117% year-on-year in the five largest economies of SEA, our 9 months 2023 cash operating expenses DECLINED by 32.6%. Just as importantly, our profit margins are materially improving on a year-to-year basis. We realized 28.1% gross profit margin in 9 months 2023, markedly improving from 9.8% in 9 months 2022.”

Mr. Liang further elaborates, “I confidently forecast profitability for our two main subsidiaries, Thoughtful Media and NusaTrip, in financial year 2023. Both subsidiaries now contribute more than 90% of SoPa’s revenues. With the Singapore launch of our SoPa Loyalty App Launch in June 2023, we are now allowing our customers to earn loyalty points through fintech/loyalty platform and our subsidiaries will translate into significant revenue generation going forward. In addition, our business plan of spinning out our main subsidiaries will generate outsized returns for our shareholders.”

SOCIETY PASS INC. (NASDAQ: SOPA) ANNOUNCES PLANS TO SPINOUT TWO PROFITABLE BUSINESS UNITS INTO NEW PUBLICLY-TRADED COMPANIES VIA NASDAQ IPOS IN 2024

NEW YORK, NY, Oct. 10, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Society Pass Inc. (Nasdaq: SOPA) (“SoPa” or the “Company”), Southeast Asia’s (“SEA”) next generation, data-driven, loyalty, fintech and e-commerce ecosystem, announces that its Board of Directors, together with its financial and legal advisors, have evaluated a comprehensive range of strategic restructuring options to unlock shareholder value. As a result of these discussions, SoPa will pursue a spinout and initial public offering on Nasdaq in 2024 for its digital advertising ecosystem, Thoughtful Media Group Inc(“TMG”), and for its online travel platform, NusaTrip Inc (“NusaTrip”).

Thailand-based TMG, the premier digital advertising network in SEA, operates in Thailand, Vietnam, Indonesia, and Philippines and connects advertisers/brands/merchants with over 10,000 influencers to targeted audiences in SEA via its social media-focused advertising ecosystem. TMG delivers significant returns on investment on advertising spend for its clients by more efficiently and effectively generating additional revenues across thousands of creator channels in industries such as fashion & beauty, lifestyle, video games, cooking, automotive, travel, luxury, and sports.

Nusatrip, a leading Indonesia-based online travel agency, offers a comprehensive range of airlines and hotels on its travel platform for corporate and retail customers across SEA. With its first mover advantage, NusaTrip has onboarded over 1.2 million registered users, over 500 airlines and over 650,000 hotels around the world as well as connected with over 80 million unique visitors. Initially only focused on the Indonesian market, NusaTrip has expanded to other SEA countries to become a first-choice travel provider throughout SEA.

SoPa believes that its separately-traded TMG and NusaTrip subsidiaries will increase SoPa shareholder value as investors can more clearly evaluate the performance and future potential of these profitable businesses on a standalone basis, whilst allowing each business to pursue its own distinct strategy and capital allocation policy. Both TMG and NusaTrip are managed by separate executive teams.

“We believe that separating and listing our principal businesses in 2024 will improve our ability to unlock hidden value for all our stakeholders,” says Raynauld Liang, the Chief Executive Officer of SoPa. “Both TMG and NusaTrip are profitable and have large and growing market opportunities. This new proposed group structure will further increase both their operational agility and ability to focus on delivering exceptional solutions to their customers.”

Mr. Liang further notes, “SoPa’s actions follow the leads of both Johnson & Johnson (JNJ) and Kellogg’s (K) spinning out operating subsidiaries and we plan on having the same success.”

CORE BUSINESS

SOPA AIMS TO MEET THE GROWING DEMAND FOR BETTER SERVICES IN ASIA BY ACQUIRING MARKET-LEADING COMPANIES AND PARTNERING WITH VISIONARY ENTREPRENEURS. THE COMPANY FOCUSES ON SIX KEY VERTICALS.

  • Loyalty

SoPa Loyalty offers a universal, open-loop loyalty platform that generates permanent customer loyalty, replaces cash discounting, and creates additional revenues for merchants. The platform helps merchants retain existing customers, attract new ones, reduce customer turnover, and sync customer data in real time. Personalized marketing campaigns are also part of the SoPa Loyalty package.

  • Digital Media

Thoughtful Media Group (TMG) is a Los Angeles-based company that operates a global multi-platform network. TMG has generated tens of millions of dollars in advertiser-branded content and deployed thousands of videos that have garnered billions of views across social media platforms such as YouTube, Daily Motion, and Facebook. It has also sourced hundreds of Asian content producers and digital media/product developers and launched brands into the markets of Thailand, Vietnam, the Philippines, China, and the US. Over the years, Thoughtful Media Group has gathered social influencer data, which it now uses to track 1 billion authenticated global video views a month across key social platforms.

  • Travel

NusaTrip is a leading online travel agency (OTA) in Southeast Asia that provides services to individuals and businesses. They have connected more than 80 million unique visitors with over 500 airlines and 200,000 hotels worldwide through various local payment options. NusaTrip has partnerships with low-cost carriers in Asia and full-service airlines globally, enabling them to offer real-time global fare shopping to help travelers find the best deals. They also work with hotel wholesalers in multiple countries to provide real-time price optimization for their customers.

  • Lifestyle

Leflair is an online shopping platform that provides access to over 3,500 Vietnamese and international brands in fashion, accessories, beauty, personal care, and home furnishings. It helps to expand markets by enabling local brands to sell their products internationally and foreign brands to enter new markets. Additionally, Leflair has filter and search programs designed to optimize the user’s shopping experience.

  • Telecom

Gorilla is a mobile virtual network operator based in Singapore that leverages blockchain and web3 technology. It has plans to expand into Malaysia, Vietnam, and Thailand and aims to increase its registered user base to over 50,000 while driving app downloads to over 20,000. Gorilla offers an innovative suite of services that include e-SIM cards, local calling, international roaming, data, and SMS texting. These services are entirely owned by the users, allowing for easy transfer or sharing via blockchain wallets.

  • Food & Beverage

In this vertical, there are three primary businesses.

  • Pushkart is a prominent online grocery delivery application in Metro Manila, with an average transaction amount of $40. This unit aims to expand its merchant coverage to 25 grocery stores, extend its reach to 10 new Philippine cities, increase its registered users to over 300,000, and boost app downloads to over 150,000.
  • Handycart is an online grocery delivery app based in Vietnam. It specializes in serving the Korean restaurant market in Hanoi. Handycart plans to expand its merchant coverage to 500 restaurants in Hanoi and aims to enter the HCMC market. Handycart is also looking to increase its registered user base to over 500,000 and drive app downloads to more than 200,000.
  • Mangan is a popular food delivery app operating on Luzon Island. It charges merchants a commission of at least 20 percent and delivery fees. On average, each transaction through the app amounts to around US$13. Mangan aims to increase its registered user base to over 500,000 and achieve over 150,000 app downloads.

NEWS

PUBLISHED

5 DAYS AGO

SOCIETY PASS INC’S (NASDAQ: SOPA) 9 MTHS 2023 FINANCIALS : REVENUES INCREASED 117% YOY; GROSS PROFIT MARGIN IMPROVED TO 28.1%; CASH OPERATING EXPENSES DECLINED 32.6% YOY

PUBLISHED

6 DAYS AGO

SOCIETY PASS INC (NASDAQ: SOPA) APPLIES TO EXTEND AN ADDITIONAL 180 DAYS TO MEET THE $1.00 MINIMUM BID PRICE REQUIREMENT

PUBLISHED

NOV 8, 2023

SOCIETY PASS INC (NASDAQ: SOPA) / NUSATRIP INC EXPANDS GEOGRAPHIC COVERAGE THROUGH STRATEGIC PARTNERSHIP WITH CHINA-BASED GUANGZHOU JUNWEI INTERNATIONAL TRAVEL SERVICE CO. LTD TO ENHANCE TRAVEL EXPERIENCE FOR CUSTOMERS IN SOUTHEAST ASIA AND CHINA

PUBLISHED

NOV 2, 2023

GREENRIDGE GLOBAL INITIATES EQUITY RESEARCH ON SOCIETY PASS INC (NASDAQ: SOPA): LOYALTY WALLET-BASED ECOMMERCE ECOSYSTEM & INFLUENCER ADVERTISING AGENCY POISED FOR OUTSIZED GROWTH IN FAST GROWING SOUTHEAST ASIA

PUBLISHED

NOV 1, 2023

SOCIETY PASS INC (NASDAQ: SOPA) AWARDED THE 2023 APEA FAST ENTERPRISE AWARD FOR E-COMMERCE CATEGORY

PUBLISHED

OCT 24, 2023

SOCIETY PASS INC (NASDAQ: SOPA) / THOUGHTFUL MEDIA GROUP INC VENTURES INTO CONCERT SPONSORING IN INDONESIA; DEVELOPING AN INNOVATIVE REVENUE STREAM AND CREATING UNIQUE MARKETING OPPORTUNITIES FOR ADVERTISERS

PUBLISHED

OCT 17, 2023

SOCIETY PASS INC (NASDAQ: SOPA) / THOUGHTFUL MEDIA GROUP INC LAUNCHES 1ST EVER MEDIAGRAM TO BUILD INDONESIA ONLINE FITNESS COMMUNITY; MEDIAGRAM PLATFORM PROJECTED TO GENERATE +20% OF TMG GROUP REVENUES IN 2024

PUBLISHED

OCT 12, 2023

SOCIETY PASS INC (NASDAQ: SOPA) ANNOUNCES EQUITY LINE OF UP TO $40 MILLION TO INVEST INTO OPERATING SUBSIDIARIES PROJECTED TO GO PUBLIC IN 2024

PUBLISHED

OCT 10, 2023

SOCIETY PASS INC. (NASDAQ: SOPA) ANNOUNCES PLANS TO SPINOUT TWO PROFITABLE BUSINESS UNITS INTO NEW PUBLICLY-TRADED COMPANIES VIA NASDAQ IPOS IN 2024

PUBLISHED

SEP 5, 2023

KEYNOTE SPEAKERS AND 34 COMPANIES TO PRESENT AT THE PLANET MICROCAP SHOWCASE: VANCOUVER ON SEPTEMBER 6-7, 2023 AT THE FAIRMONT WATERFRONT VANCOUVER

PUBLISHED

AUG 29, 2023

SOCIETY PASS INC (NASDAQ:SOPA) PRESENT AT THE PLANET MICROCAP SHOWCASE: VANCOUVER 2023 ON WEDNESDAY, SEPTEMBER 6, 2023 & 1×1 MEETINGS ON THURSDAY, SEPTEMBER 7, 2023

PUBLISHED

AUG 21, 2023

ASCENDIANT CAPITAL MARKETS: SOCIETY PASS INC. (NASDAQ: SOPA) 2Q 2023 SAW STRONG REVENUE GROWTH OF 338% YEAR ON YEAR; MAJOR ACQUISITION AND EXPECTED CASH PROBABILITY IN 2H 2023 TO DRIVE SHARE PRICE HIGHER

PUBLISHED

AUG 16, 2023

SOCIETY PASS INC (NASDAQ: SOPA)/THOUGHTFUL MEDIA GROUP INC. ENTERS PHILIPPINES MARKET AND LAUNCHES CREATOR ECONOMY FOCUSED ADVERTISING PLATFORM

PUBLISHED

AUG 14, 2023

MAXIM: SOCIETY PASS (NASDAQ: SOPA) – COMPELLING VALUATION; POSITIVE ON ORGANIC GROWTH & M&A; RAISES REVENUE TARGETS FOR 2023 AND 2024

PUBLISHED

AUG 10, 2023

SOCIETY PASS INC’S (NASDAQ: SOPA) 2Q/1H 2023 FINANCIAL RESULTS ILLUSTRATE CONTINUING BREAKNECK REVENUE GROWTH AND EXCEPTIONAL PROFIT MARGIN EXPANSION; CONFIDENTLY FORECASTS ACHIEVING CASH PROFITABILITY IN 2H 2023

PUBLISHED

AUG 4, 2023

SOCIETY PASS INC (NASDAQ: SOPA) ANNOUNCES PAYMENTS PARTNERSHIP WITH 2C2P TO ENHANCE THE ONLINE SHOPPING EXPERIENCE IN SOUTHEAST ASIA

PUBLISHED

JUL 20, 2023

SOCIETY PASS INC’S (NASDAQ: SOPA) TRAVEL SUBSIDIARY, NUSATRIP INC, ACQUIRES IATA-LICENSED VIETNAM INTERNATIONAL TRAVEL AND SERVICE JSC; ACQUISITION ADDS APPROXIMATELY US$2 MILLION IN GMV TO NUSATRIP REVENUE BASE

PUBLISHED

JUL 12, 2023

SOCIETY PASS INC (NASDAQ: SOPA): ASCENDIANT CAPITAL MARKETS INITIATES RESEARCH COVERAGE FOR SOCIETY PASS INC – US$ BILLION MARKET POTENTIAL DUE TO FAST GROWING ONLINE PLATFORM IN ATTRACTIVE SOUTHEAST ASIA MARKETS

PUBLISHED

JUL 7, 2023

SOCIETY PASS INC (NASDAQ: SOPA) SUBSIDIARY, NEXTGEN RETAIL INC, TO ACQUIRE INDONESIA’S PT INETINDO INFOCOM TO CREATE AN ONLINE AND OFFLINE ELECTRONICS AND GAMING RETAILER IN THE WORLD’S 4TH MOST POPULOUS ECONOMY

PUBLISHED

JUN 22, 2023

SOCIETY PASS (NASDAQ: SOPA) TO FORMALLY INTRODUCE SOCIETY PASS LOYALTY APP AT LAUNCH PARTY IN SINGAPORE ON WEDNESDAY, 28 JUNE 2023

MANAGEMENT  

RAYNAULD LIANG

Co-Founder / Chief Executive Officer

As Chief Executive Officer, Mr. Raynauld Liang has full P&L responsibility for the group with specific focus on general management, group strategy, acquisitions, corporate finance, control, audit, compliance and legal functions. Mr. Liang brings over 20+ years of corporate finance and investment experience.

TAN YEE SIONG

Chief Financial Officer

As Chief Financial Officer, Mr. Tan engaged in financial operation management, mergers and acquisitions, financial planning and analysis, audit and regulatory compliance and legal functions for the company. Responsible for all SEC filing matters, Mr. Tan possesses more than 15 years of audit, internal control, tax , merger & acquisition and risk mitigation experience.

PATRICK SOETANTO

Chief Operating Officer

Mr. Patrick Soetanto manages supply chain, network planning, operations planning, vendor contracts, and process improvement. He also coordinates technology, marketing, sales and finance teams to define and implement operations strategy, structure, and processes. Mr. Patrick Soetanto focuses on performance monitoring to ensure consistency with established policies, goals and objectives; and He conducts due diligence on any new business integration.

ROKAS SIDLAUSKAS

Chief Marketing Officer

As Manila and Philippines based Chief Marketing Officer, responsible for marketing, business development, PR, CRM, SEO, social media and product development coordination across business units.

HOWIE NG

Chief Technology Officer

As Group VP of Technology, manages technology team and is responsible for design/implementation of architecture, including security, database, frontend, backend and middleware, API, microservices, loyalty and payment gateways.

CHAM NGO

Vietnam GM

As Head of Leflair Business Unit, Ms. Cham Ngo oversaw the successful re-launch of Leflair onto Vietnam market in September 2021. Coordinates with Marketing/Sales, Operations and Technology teams as well as identifies partner opportunities. As Country General Manger based in Vietnam, manages country operations with P&L responsibility.

PETER DICHIARA

Chairman, General Counsel and Corporate Secretary

In his roles with Society Pass and its subsidiaries, Mr. DiChiara is responsible for leading and organizing the legal matters and the management of Society Pass and its subsidiaries.

KRIANGKRAI CHAIMONGKOL

Thoughtful Media Group Inc CEO

Joining our Company in April 2023, Mr. Chaimongkol is the CEO of Thoughtful Media Group. He is responsible for leading business operations of the company including business strategy, marketing and sales, digital planning function for the company with the main in charge of brand awareness, reputation and raising top-line growth of TMG Group in the market.

HENG YAN RONG

Thailand GM

As the general manager for Thailand. My responsibility include building and maintaining new/ existing business networks and business opportunities, handling human resource matters and managing corporate partnerships relationships, responsible for all financial related matters.

ARBIE PAGDANGANAN

VP of Product Development

As VP of Product Development, Ms. Arbie Pagdanganan is responsible for regional product development & design work of websites and apps in Society Pass ecosystem. Aligns with Marketing, Sales and Operations teams to provide consistent brand message and elevate design system. As Country General Manger based in Philippines, manages country operations with P&L responsibility.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY EDM MEDIA LLC FOR A ONE DAY SOPA AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(Nasdaq: GDC) Profile

OUR NEW PROFILE IS: (NASDAQ: GDC)

____________________

GD CULTURE GROUP EXPANDS INTO LIVESTREAMING INTERACTIVE GAMES ON TIKTOK

GDC HAS BEEN ON A SLOW AND STEADY MOVE NORTH THROUGHOUT 2023

__________________________________________

Hello Everyone,

We have another profile for you to look at and research before the open on Monday morning.

Pull up GDC.

This is another company that we have never looked at before but are excited to be able to profile it right now.

GD Culture Group Limited (the “Company”) (Nasdaq: GDC), is a Nevada holding company currently conducting business through its subsidiaries, AI Catalysis Corp. (“AI Catalysis”). The company plans to enter into the livestreaming market with focus on e-commerce and livestreaming interactive games through its wholly owned U.S. subsidiary, AI Catalysis, a Nevada corporation incorporated in May 2023.

LOOK AT THE CHART ON THIS ONE.  THE MOVE NORTH HAS BEEN SLOW AND STEADY UP FROM  THE $2 LEVEL

These are the Company’s main business:

AI-DRIVEN DIGITAL HUMAN TECHNOLOGY

The Technology is designed to create digital humans with lifelike appearances, facial expressions, and movements seamlessly bridging the gap between reality and the digital world. Powered by state-of-the-art natural language processing (“NLP”) and machine learning, these digital humans have remarkably realistic appearances through high-quality modeling, rendering, and animation.

The company aims to provide technology application services of digital human creation and customization for social media influencers or SMBs (Small and Medium-sized Businesses) in the consumer industry, to help the clients optimize their online marketing and advertising.

LIVE-STREAMING E-COMMERCE BUSINESS

The company has introduced online e-commerce businesses on TikTok. The business focus is on capturing TikTok’s popular trend by offering carefully selected product choices with smooth delivery, aiming to redefine the online shopping experience. The company formulates a dual strategy employing both short video and live streaming to offer online shoppers a more convenient and interactive shopping experience. By growing the horizontal coverage of social media platforms and vertical user base on selected product categories, the company can create value for its customers and business partners.

LIVE STREAMING INTERACTIVE GAME

The company has launched a live-streamed game on Tiktok that offers real-time and immersive gaming experience, where viewers can actively participate as players during the livestream. The company plans to diversify its game offerings and the anchor personalities for TikTok users. It aims to serve the TikTok audience 24/7 and plans to introduce digital hosts to ensure non-stop entertainment using the digital human technology.

GD CULTURE GROUP EXPANDS INTO LIVESTREAMING INTERACTIVE GAMES ON TIKTOK

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) — GD Culture Group Limited (“GDC” or the “Company”), a holding company currently conducting business through Shanghai Highlight Media Co., Ltd. (“Highlight Media”) and AI Catalysis Corp. (“AI Catalysis”), today announced that AI Catalysis has launched an interactive livestreaming game (the “Game”) on TikTok.

The Game offers real-time and immersive gaming experience. Upon joining the livestream, the Game prompts viewers to participate as players and pick one of two teams. The two player teams will compete with each other by giving commands to player avatars, challenging bosses, and purchasing in-game items to enhance gameplay. The livestream hosts offer commentary, tips and insights to excite the players. The Game has a feature allowing viewers to gift virtual tokens to their favorite hosts. The Hosts also interact with viewers’ chats and comments, which creates a sense of community. This fresh gaming style, already a hit in Asia, brings instant thrill-packed experiences to TikTok enthusiasts. The Game is easy to play, fun, and ready to entice whenever players choose to join in.

The Game has gained strong momentum and has drawn attention of many TikTok users. AI Catalysis plans to diversify its game offerings and the anchor personalities for TikTok users. Currently, the Company has collaborated with two hosts – one with humor in spades and another with a keen gaming insight. AI Catalysis aims to serve the TikTok audience 24/7 and plans to introduce digital hosts to ensure non-stop entertainment.

“We are excited to introduce this dynamic gaming experience to the TikTok community,” commented Mr. Xiaojian Wang, Chairman and Chief Executive Officer of the Company. “The synergy of real-time interaction and gaming engagement hits the sweet spot of today’s digital appetite. Moving forward, our goal is to enhance our impact on TikTok, diversify people’s way of entertainment, and deliver lasting value to our shareholders.”

NEWS

PUBLISHED

NOV 3, 2023

GD CULTURE GROUP LIMITED ANNOUNCES CLOSING OF $10 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

PUBLISHED

NOV 1, 2023

GD CULTURE GROUP LIMITED ANNOUNCES $10 MILLION REGISTERED DIRECT PRICED AT-THE-MARKET UNDER NASDAQ RULES

PUBLISHED

SEP 5, 2023

GD CULTURE GROUP EXPANDS INTO LIVESTREAMING INTERACTIVE GAMES ON TIKTOK

PUBLISHED

AUG 28, 2023

GD CULTURE GROUP LIMITED EXPANDS GRIDS OF THE FUTURE PORTFOLIO WITH TIKTOK TO DRIVE GROWTH OF LIVE-STREAMING E-COMMERCE BUSINESS SEGMENT

PUBLISHED

AUG 21, 2023

GD CULTURE GROUP LIMITED UNVEILS REBRANDING INITIATIVES REFLECTING ITS TRANSFORMATION AND FOCUS ON GROWTH AND INNOVATION

PUBLISHED

JUN 7, 2023

GD CULTURE GROUP LIMITED PARTICIPATES AND PRESENTS AT BITBLOCK SUMMIT HELD IN NEW YORK CITY ON JUNE 1, 2023

PUBLISHED

JUN 6, 2023

GD CULTURE GROUP LIMITED ESTABLISHES SUBSIDIARY IN NEW YORK TO ADVANCE OPERATIONS AND BUSINESS GROWTH

PUBLISHED

MAY 2, 2023

GD CULTURE GROUP LIMITED ANNOUNCES DOWNSIZE OF ITS REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES AND PRIVATE PLACEMENT TO $9.55 MILLION

PUBLISHED

MAY 2, 2023

GD CULTURE GROUP LIMITED ANNOUNCES $11.55 MILLION REGISTERED DIRECT PRICED AT-THE-MARKET UNDER NASDAQ RULES AND PRIVATE PLACEMENT

MANAGEMENT TEAM

Xiaojian Wang

Chief Executive Officer, President, Chairman of the Board and Director

Mr. Wang was the Vice President of Business Development at Foregrowth Inc. in Vancouver, Canada, where he formulated and executed comprehensive business plans, achieving defined sales targets and driving market expansion, conducted training sessions for financial advisors, equipping them with in-depth knowledge of compliance requirements, market insights, and product features, and conducted extensive research and due diligence on potential alternative investment opportunities, resulting in successful acquisitions and partnerships. Prior to that, Mr. Wang was a Private Banking Consultant and an Interbank Commercial Paper Trader at China Minsheng Bank in Chongqing, China. Mr. Wang received his Bachelor of Science in Mathematics degree from University of British Columbia in 2012.

Zihao Zhao

Chief Financial Officer

Mr. Zhao was a senior audit assistant at PricewaterhouseCoopers, PWC, Shanghai from 2016 to 2019. Mr. Zhao received his Bachelor of Science in Taxation degree from Shanghai Lixin University of Accounting and Finance in 2016.

Lu Cai

Chief Operating Officer

Ms. Cai has over 10 years of extensive experience in financial management and consulting. Since July 2020, Ms. Cai has been the Chief Executive Officer of Beijing Boda Shengshi Financial Consulting Co., Ltd, a firm that offers initial public offering and pre-marketing consulting services in China. From July 2017 to May 2020, Ms. Cai was a Vice President of SINO-TONE Beijing Consulting Co., Ltd, a consulting firm based in Beijing, China. Ms. Cai graduated from Beijing Foreign Studies University.

Shuang Zhang

Vice President and Director

Ms. Zhang was appointed as the Vice President and a director of the Company, effective October 4, 2022. Ms. Zhang, co-founded Highlight Media in 2016 and has been its Chief Executive Officer since 2017. During her tenure as the Chief Executive Officer, Ms. Zhang managed the planning, creation and publication of books about the company history of industry leaders in China, published in top financial publications in China. From 2015 to 2016, Ms. Zhang was the director of public relations at Ctrip, an online travel company in China. From 2004 to 2015, Ms. Zhang was the editor-in-chief of China Business News, responsible for editing, performance, and quality control. Ms. Zhang received her bachelor’s degree in journalism from Heilongjiang University in China in 1991 and her Master of Business Administration degree from the Antai College of Management and Economics of Shanghai Jiaotong University.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY SICA MEDIA LLC FOR A ONE DAY GDC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(Nasdaq: SXTP) Profile

Sixty Degrees Pharmaceuticals

OUR NEW PROFILE IS: (NASDAQ: SXTP)

____________________

SXTP HAS JUST 5 MILLION SHARES IN THE FLOAT ACCORDING TO FINVIZ

SXTP PIVOTS TO REFOCUS ON COMMERCIALIZATION OF TREATMENTS FOR MALARIA AND TICK-BORNE DISEASES

READ THE INVESTOR PRESENTATION HERE

__________________________________________

Hello Everyone,

I hope that you are paying attention.

We sent out our last profile at 2 pm Monday when the company was sitting right under 1.10.  During Tuesdays session it ran all the way up to 1.43 on above average interest after releasing news.  This was another overnight double digit run.

Moving on………………

We have a brand new company that we want you to take a look at.  This is a company that just IPO’d right before the summer and is sitting at a significant discount from it’s initial levels.

This one has a tiny float and a market cap just over $3Mill right now.

We have recently seen what happens when these low float plays pick up momentum.

Pull up SXTP.

60 Degrees Pharmaceuticals, a growth-oriented biotech company, specializes in the development and commercialization of new therapies used to treat and prevent serious infectious diseases.

Cutting-edge biological science and applied research form the foundation of our highly-focused, advanced clinical strategy.

In 2019, 60P’s malaria prevention product, ARAKODA® (tafenoquine), was made commercially available after receipt of U.S. regulatory approval in 2018.

Our current product development targets include tick- borne, viral, fungal and other serious infectious diseases with unmet needs we perceive in the marketplace.

PORTFOLIO

Investment Highlights

▪ ARAKODA – a long-acting, potentially broad-spectrum, anti-infective already FDA-approved for malaria prevention and commercially available in the U.S.

▪ Safe, long acting, mechanistically differentiated antimalarial approved by FDA
▪ Discovered by US Army and successfully brought to market by 60P
▪ 1,100+ patient exposures in 8+ published clinical trials, weekly dosing for up to one year
▪ Commercially available in U.S. via network of major national distributors
▪ Existing commercial/regulatory infrastructure expected to facilitate cost-effective pathway to new/expanded indications following targeted clinical trial and label changes

▪ Arakoda Regimen of Tafenoquine – Research agenda involving babesiosis and other diseases
▪ Malaria, COVID-19, fungal, tick-borne illness of interest to the Company affect millions and are associated with a potentially high revenue unmet medical need ▪ Company has strong IP for malaria, COVID-19, and other indications
▪ Accelerated clinical recovery from babesiosis is suggested by case studies of immunosuppressed patients administered tafenoquine
▪ 2024: Execute Phase IIA treatment study in hospitalized babesiosis patients
▪ 2025: sNDA and/or confirmatory babesiosis patient study

▪ Experienced management team and Board
▪ Team has together led/managed four clinical trials
▪ Collectively led multiple pharmaceutical product approvals/product launches ▪ Collectively led/provided guidance on 20+ public & private entities
▪ Participated in/led multiple public listings

Intellectual Property & Licensing

60 Degrees Pharmaceuticals has freedom to operate

  • U.S. Arakoda Patents (2 issued/6 in progress)
    • T afenoquine for malaria prevention patent family: Earliest expiration December 2034
    • Tafenoquine for lung Infections/COVID Treatment: Earliest expiration March 2041
  • U.S. Celgosivir Patents
    • Dengue/RSV (4 issued/2 in progress)
  • International Patents

■ 6/2 for Celgosivir issued/in progress, 1/8 for tafenoquine issued/in progress

■ Clinical, non-clinical and manufacturing information

60 DEGREES PHARMACEUTICALS SUSPENDS PHASE IIB STUDY OF TAFENOQUINE FOR COVID-19, PIVOTS TO REFOCUS ON COMMERCIALIZATION OF TREATMENTS FOR MALARIA AND TICK-BORNE DISEASES

October 12, 2023 at 4:16 PM EDT

  • FDA advice to Company suggested execution of ACLR8-LR, a placebo-controlled Phase IIB study of tafenoquine in COVID-19 patients, may not be feasible in the U.S.
  • Company will therefore focus efforts on further commercialization related to ARAKODA® (tafenoquine) for prophylaxis of malaria, and prepare for a Phase IIA study of tafenoquine in hospitalized babesiosis patients
  • Company is preparing for submission of a pre-IND meeting request with FDA for babesiosis in the current fourth quarter of 2023, and plans to appoint a chief commercial officer to lead ARAKODA commercialization

WASHINGTON, Oct. 12, 2023 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced that its subsidiary, 60P Australia Pty Ltd, will not re-submit its investigational new drug application (“IND”) for ACLR8-LR, a Phase IIB study of tafenoquine compared to placebo in patients with mild to moderate COVID-19 disease and low risk of disease progression. Tafenoquine is the active molecule in ARAKODA®, the Company’s U.S. Food and Drug Administration (FDA)-approved regimen for malaria prevention. The Company’s Board of Directors decided on October 6, 2023, that recent advice from the FDA made moving forward with the ACLR8-LR clinical development plan unfeasible.

The FDA has approved or authorized two marketed oral products, Lagrevio™ and Paxlovid™, for use in cases of mild-to-moderate COVID-19 disease to reduce the rate of hospitalizations and deaths in patients with high risk of disease progression. However, the FDA has explicitly not authorized the use of those products in patients with low risk of COVID-19 disease progression. Accordingly, Lagrevio and Paxlovid are not recommended by public health agencies for that purpose.

Current literature on COVID-19 shows that low risk patients have a very low risk of hospitalization. However, patients may wish to make a risk-based decision together with their physician to use a therapeutic that accelerates clinical recovery from COVID-19 symptoms if such a therapeutic were available. FDA guidance for industry implies that a regulatory pathway does exist for approval of new therapeutics that produce “sustained clinical recovery” in COVID-19 patients. FDA-approved or authorized oral therapies have either failed or have not been studied against that endpoint.

60P’s early, published Phase IIA clinical data suggested the possibility of a 2 – 2.5 day improvement in clinical recovery from cough, fever, and shortness of breath.1 Simulations of data from the same study suggested this might also be the case for the FDA’s preferred endpoint of “sustained clinical recovery” from all acute symptoms excluding impaired taste and smell (see accompanying figure).

However, in a recent IND withdrawal acknowledgement letter from the FDA, the agency implied that a placebo-controlled study in the U.S. is permissible only if study enrollment is “restricted to a patient population in which nirmatrelvir/ritonavir or other approved or authorized therapeutics are not clinically appropriate.”

As a practical matter, the population of patients in the U.S. with medical contraindications to Paxlovid™ and Lagevrio™ is vanishingly small, which would make patient recruitment very challenging. The Company also considered the FDA’s recommended approach of a standard of care add-on design. However, such a combination approach may not make clinical sense in a low-risk population or be Phase III enabling. In either case, the Company’s Board of Directors determined that raising capital to support a protracted development campaign, or one requiring three additional studies, was not feasible in the current market environment.

Accordingly, as outlined in its registration statement and subsequent communications to the investment community, 60P will instead continue to prepare to conduct a Phase IIA study of tafenoquine in hospitalized babesiosis patients, with the goal of requesting a pre-IND meeting with FDA before the end of 2023.

An estimated 47,000 cases of babesiosis (infections caused by red blood cell parasites similar to malaria that are transmitted by deer tick bites) occur in the United States each year, and the incidence rate is increasing. Estimates are that 10 percent of Lyme disease patients are co-infected with babesiosis. Post-exposure prophylaxis following a tick bite is a recognized indication to prevent Lyme disease, and it is likely that a drug proven to be effective for this indication for babesiosis would also be used in conjunction with Lyme prophylaxis.

60P also intends to hire a commercial operations executive to expand its commercialization efforts related to ARAKODA (tafenoquine), an antimalarial indicated for prophylaxis of malaria in patients 18 years and older and approved by the FDA in 2018. In the second quarter of 2023, sales of ARAKODA increased by 150 percent relative to the same period in 2022, at an accelerating growth rate.

NEWS

PUBLISHED

OCT 19, 2023

60 DEGREES PHARMA TO PRESENT REVIEW OF SAFETY, EFFICACY DATA OF 8-AMINOQUINOLINES FOR MALARIA AND BABESIOSIS TREATMENT AT ILADS ANNUAL SCIENTIFIC MEETING IN BOSTON

PUBLISHED

OCT 12, 2023

60 DEGREES PHARMACEUTICALS SUSPENDS PHASE IIB STUDY OF TAFENOQUINE FOR COVID-19, PIVOTS TO REFOCUS ON COMMERCIALIZATION OF TREATMENTS FOR MALARIA AND TICK-BORNE DISEASES

PUBLISHED

SEP 18, 2023

60 DEGREES PHARMA WITHDRAWS COVID PHASE IIB IND, WILL RESUBMIT PENDING ASSESSMENT OF ABILITY TO MEET FDA REQUIREMENTS

PUBLISHED

SEP 6, 2023

60 DEGREES PHARMACEUTICALS TO PARTICIPATE IN H.C. WAINWRIGHT 25TH ANNUAL GLOBAL INVESTMENT CONFERENCE

PUBLISHED

SEP 1, 2023

GENETIC TECHNOLOGIES LIMITED AND 60 DEGREES PHARMACEUTICALS INTERVIEWS TO AIR ON THE REDCHIP MONEY REPORT(R) ON BLOOMBERG TV

PUBLISHED

AUG 30, 2023

60 DEGREES PHARMACEUTICALS STUDY RESULTS PUBLISHED BY NEW MICROBES AND NEW INFECTIONS DEMONSTRATE TAFENOQUINE EXHIBITS BROAD SPECTRUM ANTIFUNGAL ACTIVITY

PUBLISHED

AUG 22, 2023

60 DEGREES PHARMACEUTICALS RECEIVES ADDITIONAL U.S. PATENT COVERING TAFENOQUINE FOR PREVENTION OF PLASMODIUM FALCIPARUM MALARIA

PUBLISHED

AUG 15, 2023

60 DEGREES PHARMACEUTICALS REGISTERS ACLR8-LR, A PHASE IIB STUDY OF TAFENOQUINE FOR TREATMENT OF COVID-19, ON CLINICALTRIALS.GOV

PUBLISHED

JUL 31, 2023

60 DEGREES PHARMACEUTICALS AWARDED CANADIAN PATENT COVERING TAFENOQUINE FOR PREVENTION OF MALARIA IN MALARIA-NAIVE SUBJECTS

PUBLISHED

JUL 21, 2023

60 DEGREES PHARMACEUTICALS AND UNICYCIVE THERAPEUTICS INTERVIEWS TO AIR ON BLOOMBERG TV ON THE REDCHIP MONEY REPORT(R)

PUBLISHED

JUL 14, 2023

WALLACHBETH CAPITAL ANNOUNCE CLOSING OF 60 DEGREES PHARMACEUTICALS IPO AT $5.30 PER UNIT

PUBLISHED

JUL 14, 2023

60 DEGREES PHARMACEUTICALS ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING

MANAGEMENT TEAM

Geoffrey Dow

Chief Executive Officer & President

Geoffrey Dow is the CEO, President, and a Director of 60 Degrees Pharmaceuticals, Inc. (60P). He has over 20 years of experience in product development for tropical diseases and a strong publication and patent history. He has 13 years of leadership and advisory experience in the antimalarial drug development program at the Walter Reed Army Institute of Research and the U.S. Army Medical Materiel Development Activity. Dr. Dow co-founded 60P in 2010 and has been instrumental in various projects including securing FDA-regulatory approval for tafenoquine (Arakoda) for malaria prophylaxis, managing post-marketing regulatory commitments, and ensuring the company adheres to GMP, quality, and pharmacovigilance requirements. He has also published several important safety reviews, clinical trials, and non-clinical studies. Dr. Dow’s ultimate goal is to develop and secure regulatory approval and commercial success of products for new indications in infectious disease. He holds a B.Sc. (Hons) in Veterinary and Biomedical Science from Murdoch University, Perth, Western Australia (1994), a Ph.D. in Veterinary and Biomedical Science from Murdoch University (2000), and an MBA from the University of Maryland at College Park (2012).

Bryan Smith

Chief Medical Officer

Bryan Smith is the Chief Medical Officer of 60 Degrees Pharmaceuticals, Inc. (60P). He is a medical doctor with expertise in clinical pharmacology, pharmacovigilance, regulatory strategy development, and translational medicine. He has over 30 years of experience in governmental research and leadership and is a retired military colonel. He joined the company in 2016 and works with the senior management team to establish all functional areas, including compliance with laws and regulations and overseeing research and development projects. Dr. Smith is also a Senior Medical Director, Clinical and Regulatory Affairs at Fast-Track Drugs & Biologics, LLC since 2019, where he is responsible for developing clinical development plans, managing clinical and regulatory projects, and designing and writing clinical trial protocols. He has also served as the Chief Medical Officer and member of Amivas LLC, where he established all functional areas required to secure FDA approvals. Additionally, from 2016 to 2019, he was the Principal Medical Consultant at Clinical Network Services, Inc. where he provided medical, clinical pharmacology, regulatory, and translational medicine review, oversight and consultation as requested for over 25 unique clients in a range of activities and tasks for devices, small molecules, and large molecules in a range of therapeutic areas. He holds a Bachelor of Science in General Science, with highest honors, from Oregon State University and a Doctor of Medicine from Uniformed Services University of the Health Sciences.

Tyrone Miller

Treasurer

Tyrone Miller is the Treasurer of 60 Degrees Pharmaceuticals, Inc. (60P). He joined the company in 2014 and has held various roles including Chief Financial Officer. He has experience raising over $6 million in external financing and established a multinational financial reporting system. He provides strategic advice in areas of financing and business planning to the company. He is also the founder and Principal of Tax & Accounting Practice at Miller Tax & Advisory since 2011, where he advises business owners on accounting, financial, and tax matters and has designed accounting systems for private businesses. Prior to that, he was a Senior Accountant at Sachs Figurelli, LLC from 2002 to 2011 where he prepared and processed corporate and individual tax returns, consulted on accounting processes for various businesses, and managed staff in preparation and processing of payroll and personal property returns. He is a Certified Public Accountant and received a Bachelor’s of Business Administration with a concentration in International Business from Emory University in 1996.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWELVE THOUSAND FIVE HUNDRED USD BY SICA MEDIA LLC FOR A ONE DAY SXTP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(Nasdaq: NNVC) Profile

OUR NEW PROFILE IS:   (NYSE AMERICAN: NNVC)

NV-387 IS HIGHLY ACTIVE AGAINST TESTED CORONAVIRUSES INCLUDING SARS-COV-2 IN PRE-CLINICAL STUDIES

THE ENTIRE FLOAT ON NNVC IS JUST 11.2 MILL ACCORDING TO FINVIZ!!!!

READ THE INVESTOR PRESENTATION HERE

______________________________________________________________

Hello Everyone,

We have another new profile that we want you to research right away.  This is one you should research immediately.

This is a company that we have never profiled on this newsletter before.

NNVC has several promising catalysts that we want you to take a look at right away.  

This one has a small float and a history of volatility like several of our latest profiles.

NEW ERA IN TARGETED ANTI-VIRAL THERAPEUTICS  

NanoViricides, Inc. is a globally leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology enables direct attacks at multiple points on a virus particle. It is believed that such attacks would lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody. In addition, the nanoviricide technology also simultaneously enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is the only technology in the world, to the best of our knowledge, that is capable of both (a) attacking extracellular virus, thereby breaking the reinfection cycle, and simultaneously (b) disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.

Our anti-viral therapeutics, that we call “nanoviricides®” are designed to appear to the virus like the native host cell surface to which it binds. Since these binding sites for a given virus do not change despite mutations and other changes in the virus, we believe that our drugs will be broad-spectrum, i.e. effective against most if not all strains, types, or subtypes, of a given virus, provided the virus-binding portion of the nanoviricide is engineered appropriately. Viruses would not be able to escape the nanoviricide by viral mutations since they continue to bind to the same cellular receptor and thus would be captured by the nanoviricide. Virus escape by mutations is a major problem in the treatment of viral diseases using conventional drugs.

FINVIZ HAS THE ENTIRE FLOAT AT JUST 11.2 MILLION.  THAT WOULD EXPLAIN THE VOLATILITY ON THE CHART.  YOU WILL NOTICE THAT THIS ONE HAS BOUNCED OFF OF THE LOWS SEVERAL TIMES IN THE PAST YEAR.

NOTEWORTHY CATALYSTS

  • Broad-Spectrum, Pan-Coronavirus Drug NV-CoV-2 (API NV-387) for COVID, certain cases of long COVID, Seasonal Coronaviruses, MERS is in Clinical Trials. Two formulaJons are in clinical trials at present: Oral Syrup which can be titrated for body weight and is therefore preferable in pediatric seeng, and Oral Gummies, a fixed strength dosage form generally preferable for adults. We believe they would be highly effecJve for mild-to-moderate (non-hospitalized) cases of COVID. AddiJonally, NV-CoV-2 Solu=on for Injec=on, Infusion, and Inhala=on is developed for hospitalized COVID patients with severe disease; direct lung inhalaJon should provide significantly superior benefits by providing high pulmonary local concentraJon of the drug. NV-CoV-2 (NV-387) was found to have strong effecJveness in mulJple coronaviruses in vitro, and also strong effecJveness even when compared to remdesivir in animal studies of lethal lung infecJon. We believe the human clinical trial results should be consistent with these pre-clinical studies, and if so, would establish NV-CoV-2 as perhaps the most effecJve COVID treatment. There is no safe and effecJve COVID drug that covers all the paJent populaJons and disease severiJes at present, indicaJng significant unmet medical needs.
  • NV-387 Expanded Indications Program. We are elucidating the breadth of the anJviral spectrum of NV-387 at present. NV-387 is based on mimicking sulfated proteoglycans to a_ack the virus parJcle. A large number of viruses bind to such structures before gaining cell entry, including RSV, human MetaPneumoVirus (hMPV), certain Adenoviruses, other respiratory pathogens, as well as a number of systemic viruses such as Dengue viruses, Chickengunya, among others. Successful addiJonal indicaJons against any such viruses, if any, would significantly improve the return on investment, while fulfilling unmet medical needs.
  • Such additional indications would be eligible for Phase II/III studies with NV-387 having completed Phase I studies already.
  • Additonally, NV-387-R Could Result in Potential Cure Against a Number of Non-Latency Viruses.
  • HerpeCideTM Program. Variants of NV-HHV-101 are expected to become clinical drug candidates for topical treatment of HSV-2 “genital ulcers”, and HSV-1 “cold sores” soon aqer NV-HHV-101 goes into clinical studies. NV-HHV-101 is anJcipated to further expand into additional indications against chickenpox – a possibly orphan drug in the USA – and PHN (a morbidity of shingles persistent pain that may last for six months or longer, aqer the rash resolves).
  • We are also developing drugs against HIV.
    NanoViricides, Inc. is possibly the first in the world to have developed an orally effecJve nanomedicine.

VERSATILE PLATFORM TECHNOLOGY

A nanoviricide is created by chemically attaching a virus-binding ligand, derived from the binding site of the virus on its cell surface receptor, to a nanomicelle flexible polymer. This binding site does not change significantly when a virus mutates

Tailor-made design and selection of (1) the virus-binding ligand; and (2) the backbone “nanomicelle”, separately, allows us to rapidly optimize drug candidates (a) against a number of viruses; (b) for desired pharmacokinetic characteristics (e.g. sustained effect); and (c) for different routes of administration. This versatility is unmatched in the Industry.

Virus-specific nanoviricides have been created against important viruses such as HIV, Influenza and Bird Flu by choosing highly virus-specific ligands

Broad-spectrum nanoviricides have been created that can bind to possibly as many as 90-95% of known viruses. The Company is developing broad-spectrum nanoviricides to combat several neglected tropical diseases, such as Dengue, Rabies, and Ebola/Marburg. This is similar to antibiotics such as penicillin against bacteria that exploit a feature common to all bacteria.

NANOVIRICIDES BROAD SPECTRUM ANTIVIRAL COULD CHANGE HOW WE TREAT VIRAL INFECTIONS

So far, NanoViricides has built a robust foundation of promising preclinical research that demonstrates the unique antiviral platform’s potential to treat not just COVID-19 but a wide range of other common and hard-to-treat viral diseases like other coronaviruses, RSV, shingles, herpes, rabies and the flu.

The reason it could have such broad applicability is because the NanoViricides platform was specifically designed to target a particular binding site that’s common across many viruses and doesn’t change even as a virus mutates. Essentially, the nanoviricide platform mimics the binding site on a human cell that a virus would normally target in order to infect that cell. Then it seeks out the virus and when the virus binds to the nanoviricide instead, the drug candidate immediately engulfs the virus, where it’s unable to infect the patient’s cells or reproduce.

THE FIRST OF THESE DRUGS IS NOW IN HUMAN PHASE 1A AND 1B CLINICAL TRIALS

The Phase 1a/1b clinical trial includes single-ascending dose (SAD) and multiple-ascending dose (MAD) safety and tolerability studies in healthy subjects. NanoViricides reported that 26 of the 36 volunteers in the SAD study and 17 of the 36 volunteers in the MAD study have already completed the program. And so far, the early data looks promising. Neither adverse events nor serious adverse events have been found to date in either study.

“The excellent safety and tolerability of NV-CoV-2 in both formulations in the clinical trials is consistent with the results of pre-clinical animal studies, giving us confidence that our preclinical animal studies can be expected to be predictive of human clinical trials,” said NanoViricides Executive Chairman and President, Anil R. Diwan, Ph.D.

ONGOING PHASE 1A AND 1B CLINICAL TRIALS WILL GIVE FIRST INDICATION OF NANOVIRICIDES EFFICACY IN HUMANS

With that baseline of safety and tolerability, the next part of the trial is to enroll COVID patients in the trial and start evaluating whether the positive preclinical effectiveness results for the drug will translate to human trials. Once this trial is finished, NanoViricides plans to seek permission to move into phase 2 clinical trials from multiple regulatory agencies worldwide.

Of note, the same drug was found to be effective in pre-clinical studies against another important respiratory virus, RSV. Such a broad spectrum antiviral effectiveness is reminiscent of the development of antibiotics against bacteria. This could be a game-changing development in antiviral therapeutics.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

NANOVIRICIDES TREATMENT FOR RSV

NanoViricides (NYSE American: NNVC), a leading developer of antiviral treatments through its nanomedicines platform, is developing a safe and effective alternative therapeutic for RSV. Its drug candidate, NV-387, has already been shown to not have the toxicity or side effects associated with Ribavirin, according to the company. It reports that in the recent pre-clinical animal study, NV-387 almost matched the efficacy of Ribavirin with no toxicity. This animal study was designed to mimic the lethal lung pneumonia in infants caused by RSV infection.

Importantly, NV-387 is already in phase 1 human clinical trials as the active ingredient in the company’s COVID drug candidate NV-CoV-2. The company has just reported that it was found to be completely safe, with no side effects found to date, in this continuing phase 1 Study. For this reason, the company anticipates soon being able to advance NV-387 to a phase 2 human clinical trial against RSV.

If the results of animal studies are replicated in humans, this nanoviricides drug could become truly a game-changer in the treatment of RSV infections.

CGMP PRODUC=ON IN MUL=-KILOGRAM SCALE IN OUR OWN FACILITY

We have completed producJon of the drug in mulJ-Kg quanJJes for the GLP porJon of the IND enabling Safety/Toxicology studies. This producJon was performed under cGMP-compliant condiJons in our State of the Art cGMP-capaead on, by building our own capability. We believe we have thus minimized the manufacturing risk for our en=re pla4orm technology.

ble Manufacturing Facility for Clinical Drug Produc=on in Shelton, CT. We have engaged in the producJon of the cGMP manufactured drug product for the upcoming human clinical trials at this plant. cGMP Manufacturing capability is a major risk for new pharma companies, especially in nanomedicines. We are happy to report that we are tackling this risk hThe NanoViricides facility in Shelton, CT, contains customizable mulJ-product cGMP manufacturing

capability, as well as advanced nanomedicines characterizaJon and R&D laboratory, to support clinical drug
manufacture of any of our drug candidates, enabling cost-effecJve, speedy entry to clinic. Moreover, its
Manufacturing Scale is more than sufficient to support ini=al marke=ng needs, enabling early revenues upon drug approval.

GLOBAL, STRONG, PIONEERING, INTELLECTUAL PROPERTY WITH RUNWAY BEYOND 2040

Strong Global Intellectual Property Posi=on with Drug Patents to Expire Beyond 2040

All of our drug candidates are based on broad & exclusive world-wide licenses in perpetuity from TheraCour Pharma, Inc. The licensed fields include human diseases of COVID, VZV, HSV-1, HSV-2, all Influenza viruses including H5N1 and pandemic H1N1, HIV, Dengue, Ebola, Marburg, Rabies, etc. These licenses are extremely broad and cover development of drugs a_acking the stated virus in pathological indicaJon benefieng from viral load reducJon. NanoViricides intends to own the regulatory drug licensure (use of enJty for indicaJon), and may commercialize the same on its own or further sublicense to other Pharma companies.

NanoViricides has exclusive worldwide licenses from TheraCour Pharma, Inc., to field-defining, pioneering, proprietary intellectual property and global patent applicaJons, that have already issued into 61 patents in countries including the U.S., Australia, Japan, China, Canada, and all of Africa. Issued patents are “first-in-class” with no prior art, showcasing the Company’s leadership posiJon in this field. The patents cover broad composiJons of ma_er, methods of making, and uses. The first of the fundamental patents has expiraJon date in 2026. We have begun to patent IP estate around each of our drug candidates separately. Two internaJonal PCT patent applicaJons have been made for the COVID space; resulJng patents would expire in 2040. AddiJonal applicaJons are expected soon. This provides substanJal runway for commercial realizaJon.

UNIQUE, NOVEL, POST-IMMUNOTHERAPEU=C “BIND-ENCAPSULATE-DESTROY” MECHANISM ENABLES FIRST-IN-CLASS PRODUCTS

Beyond An=bodies and Vaccines: AnJbodies have been developed as drugs against viruses. However, each anJbody only binds by two points to the virus, and destrucJon of the complex requires effecJve immune funcJon, which is not the case in sickness. Vaccines only train the body into producing anJbodies against the virus in the vaccine. AnJbodies and vaccines are easily overcome by viruses by mutaJng in the field as is now well known from COVID.

A Nanoviricide is A Nanomachine that Completes the Task of Destroying Virus without Help from the Pa=ent’s Immune System Key Issue of Drug Resistance from Viral Muta=ons is Unlikely with Nanoviricides Drugs due to Unique Biomime=c Technology

In contrast, a nanoviricide should work against all strains of the virus because they sJll bind the same way to the same host cell receptor. The nanoviricide® technology plalorm mimics the host cell. We design and develop a virus-binding ligand that mimics the site on the host cell receptor to which the virus binds. This ligand is then chemically a_ached to a special polymer to make a nanoviricide®. The virus is expected to be fooled into binding to the nanoviricide, like a venus-fly-trap. The nanoviricide is then expected to engulf the virus and possibly destroy it. A nanoviricide a_acks the virus with hundreds of virus-binding sites on its surface. The nanoviricide is capable of dismantling the virus, and the resulJng complexes are fully biodegradable in the body.

Not shown here, is a nanoviricide’s ability to encapsulate drugs inside it, protect them from bodily environments, and deliver them as per design. This ability can be harnessed to develop cures for many viruses.

NANOVIRICIDES, INC. HAS FILED ITS ANNUAL REPORT: BROAD-SPECTRUM ANTIVIRAL NV-387 (NV-COV-2) IN PHASE 1A/1B CLINICAL TRIAL IS HIGHLY ACTIVE AGAINST CORONAVIRUSES AS WELL AS RSV

SHELTON, CONNECTICUT — Monday, October 16, 2023 — NanoViricides, Inc. (NYSE Amer.: NNVC) (the “Company”), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023 with the Securities and Exchange Commission (SEC) on Friday, October 13, 2023. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057823002146/nnvc-20230630x10k.htm ).

We reported that, as of June 30, 2023, we had cash and cash equivalent current assets balance of approximately $8.15 Million. In addition, we reported approximately $8.1 Million in Net Property and Equipment (P&E) assets (after depreciation). The strong P&E assets comprise our cGMP-capable manufacturing and R&D facility in Shelton, CT. The total current liabilities were approximately $0.53 Million. In comparison, as of June 30, 2022, we had cash and cash equivalent balance of approximately $14.4 Million, P&E assets of approximately $8.7 Million (after depreciation), and total current liabilities of approximately $0.41 Million.

We estimate that we have sufficient funds to complete the on-going human clinical trials for our lead drug candidate NV-CoV-2 which is the drug product based on our “nanoviricide” active pharmaceutical ingredient (“API”), NV-387.

We believe that the successes of NV-387 as a broad-spectrum antiviral (see below) bode well for validating the multiple modalities in which our Nanoviricides Platform Technology can be employed to revolutionize the treatment of viral infections as well as pandemic preparedness response.

We believe that NV-387 works by a novel mechanism of action, that of blocking the re-infection cycle of the viral disease. We believe that NV-387 not only binds to the virus, but fuses with the virus surface, uprooting the glycoproteins that are required for the virus to bind to the human cell (for example, the S protein, and its products S1 and S2 proteins from coronaviruses), thereby rendering the virus incapable of infecting a cell. In contrast, antibodies are only capable of covering the virus, generally incompletely, and require immune system assistance for clearing the resulting complex.

We believe that NV-387 mimics the “Sulfated Proteoglycans” (“S-PG”) family of virus attachment receptors. This family includes heparan sulfate (HSPG), dermatan sulfate (DSPG), chondroitin sulfate (CSPG), and keratan sulfate (KSPG). Over 90% of known pathogenic viruses bind to one or more of these S-PG class attachment receptors. These viruses include Coronaviruses, Paramyxoviruses (RSV – Respiratory Syncytial Virus, and HMPV- human Metapneumovirus), Dengue Viruses, Herpesviruses, Human Papillomavirus (HPV), HIV, Hendra and Nipah Viruses, Ebola and Marburg Viruses, among others. Therefore, NV-387 may be anticipated to exhibit strong antiviral activity against at least some, if not many, of these viruses.

We have found that NV-387 is highly active against tested coronaviruses including SARS-CoV-2 in pre-clinical studies. We are expanding our pre-clinical studies to evaluate the antiviral activity of NV-387 against other viruses. We believe that this work would expand the range of indications for NV-387. Such expansion of use of NV-387 would significantly expand the market size and substantially improve the return on investments (ROI).

We have already found that NV-387 is highly effective against a lethal lung infection by RSV in an animal study, a result which is expected to add significantly to the commercial potential of NV-387 if the drug proves out further in clinical studies. We believe that we will be able to take RSV into Phase 2 clinical studies once the current Phase 1 studies are completed.

We believe that NV-387 has a broad spectrum of antiviral activity that is reminiscent of the antibacterial activity of antibiotics. We believe that the Nanoviricides Platform Technology is poised to revolutionize the fight against viruses just as antibiotics revolutionized the fight against bacterial infections. Antibiotics attack a bacteriological common feature, the peptidoglycan wall, of bacteria. Analogously, NV-387 is designed to attack a virological common feature, the binding of viruses to S-PG family attachment receptors.

RSV is an important pathogenic virus that can cause lethal infection in infants as well as seniors and immunocompromised persons. Two different vaccines against RSV have been recently approved by the US FDA, but none are for pediatric use at present. Two different antibodies have been approved as prophylactic (i.e. to prevent RSV infection) for babies, but are not approved as therapeutics (i.e. after disease occurs). There is no safe and effective therapeutic available for RSV. Ribavirin, a highly toxic drug that attacks red blood cells and can cause multi-organ failures is reserved for use as a last resort only in extremely severe hospitalized cases of RSV. NV-387 was almost as active as ribavirin. Additionally, NV-387 has been found to be extremely safe in pre-clinical studies. Thus, we believe NV-387 could be a clinical quality drug candidate for the treatment of RSV infections.

GrowthPlus Reports, in June 2023, said the market size for RSV therapeutics was worth $1.8 Billion in 2022, and is expected to grow at a CAGR of 18.9%, reaching $8.73 Billion by 2031.

NV-387 is in Phase 1 human clinical trial as two oral formulations: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies in India. The drug sponsor, Karveer Meditech Pvt. Ltd., is our licensee and collaborator and has the rights to develop and commercialize the drugs in India. As of now, 26 out of a target of 36 healthy human subjects have completed the clinical trial. There were no reports of adverse events or serious adverse events, indicating both of these formulations and the API NV-387 are extremely safe in humans. These results are consistent with our pre-clinical safety/toxicology animal studies.

In addition to the S-PG family, another important attachment receptor family is “Sialylated Glycoproteins”. Influenza viruses, some pathogenic Adenoviruses that cause epidemic kerato-conjunctivitis (EKC), as well as a large number of other viruses bind to sialic acid which is the terminal part of these receptors. We are making headways in developing nanoviricides that mimic this class of receptors.

We call the broad-spectrum nanoviricides based on such general features as the S-PG and the Sialic based receptors that are widely used by viruses for attachment as “Modality #1” of the application of nanoviricide platform technology. This modality is expected to result in very broad spectrum antiviral agents, as evidenced by NV-387.

In another methodology, that we call “Modality #2”, we have developed nanoviricides that specifically bind to a specific type of virus, mimicking the cell-surface receptor to which the virus binds in order to gain entry into cells (called the “cognate” receptor). We have developed NV-HHV-1 as an antiviral that is active against certain herpesviruses. NV-HHV-1 has completed IND-enabling studies. Its first indication, formulated as a skin cream, is for the treatment of Shingles rash. It has been found to be active against HSV-1 (“cold sores”), HSV-2 (“genital herpes”) and VZV (Chickenpox and Shingles) in pre-clinical studies. We have also developed an anti-HIV drug candidate that mimics CD4 which is used by HIV.

No matter how much a virus mutates, changes, or generates new variants, it continues to utilize the same attachment receptor(s) and the same cognate receptor(s) and, further, binds to the receptor(s) at the same locations. Thus, the virus is expected to be unlikely to escape a nanoviricide drug if our nanoviricide properly mimics the location on the cellular receptor that the virus uses.

This very much sought-after feature sets apart our Nanoviricides Platform Technology from other antiviral approaches. The virus learns to escape readily the battery of conventional approaches, which is comprised of antibodies, vaccines, and small chemical drugs, as has been amply evidenced in the COVID-19 pandemic, the recurring Influenza pandemics and epidemics, the on-going HIV pandemic, and other instances.

We are particularly excited about our “Modality #3” of applying the Nanoviricide Platform Technology that we believe will enable true cures for a large number of viral infections. In this modality, we have been able to create a nanoviricide that (i) blocks the virus particle from infecting a new cell in the first place, and (ii) holds in its belly another API that blocks the virus that has infected a cell from making and releasing its copies. We believe such a nanoviricide would be a true cure for infections of viruses that do not generate latent infections in the body. This modality goes beyond the conventional approach of treating a patient with multiple drugs simultaneously, in at least two ways: (i) as an infrequent single drug treatment that improves patient compliance, and (ii) by virtue of the improvement in the pharmacokinetics of the guest API due to the nanoviricide encapsulant. We have already demonstrated that NV-387-g-R, which is remdesivir as guest encapsulated within the polymeric micelle of NV-387, protects remdesivir from bodily metabolism.

In a fourth modality, we are conducting preliminary research to harness the power of the Nanoviricide Platform Technology to cure latent virus infections as well.

We have not only established a broad and expanding antiviral drug pipeline, led by NV-387 for coronavirus infections (clinical), NV-387 for RSV infections (advanced pre-clinical), and NV-HHV-1 for treatment of Shingles rash (IND-enabling), and many other pre-clinical drug candidates, but have also developed the Nanoviricide Platform Technology to the level that cures against many virus infections can now be envisaged.

We have made significant progress despite limited resources in our endeavor of curing viral infections using the power of the Nanoviricide Platform Technology, and this year, we have been able to take the first nanoviricide drug into human clinical trials. We believe this opens a new era in the development of NanoViricides, Inc. We plan on seeking non-dilutive as well as equity-based funding as we go forward in this quest.

What is a “nanoviricide”?
A “nanoviricide” is a uniform polymer that self-assembles into nanoscale droplets called “micelles”, that carries on its surface mimics of the cell-side receptor of the virus, and that hides in its belly lipid tentacles. It can also hold other guest APIs in its belly if needed. The nanoviricide thus “looks like” a cell to the virus, and the virus is fooled into binding it. Once the virus binds, we believe, the flexible and shape-shifting nanoviricide micelle would spread over the virus particle by virtue of merging the lipid tentacles that are hidden in its belly into the virus surface, in a well known process called “lipid-lipid mixing.” We believe this would destabilize the virus particle, uproot the viral glycoproteins required for binding to and entering the host cell, and thus render the virus particle incapable of infecting a cell.

About NanoViricides, Inc.
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Our other advanced candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of factors including external collaborators and consultants. NV-CoV-2 is currently in Phase 1a/1b clinical trial sponsored by our licensee and collaborator, Karveer Meditech, Pvt. Ltd., India.

NV-CoV-2 is our nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2 does not contain remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including RSV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and human Coronaviruses. The Company intends to obtain a license for poxviruses, RSV, enteroviruses, and others as and when the Company determines to further advance the drug development opportunity, if the initial research is successful. The Company’s technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

NEWS

PUBLISHED

OCT 16, 2023

NANOVIRICIDES, INC. HAS FILED ITS ANNUAL REPORT: BROAD-SPECTRUM ANTIVIRAL NV-387 (NV-COV-2) IN PHASE 1A/1B CLINICAL TRIAL IS HIGHLY ACTIVE AGAINST CORONAVIRUSES AS WELL AS RSV

PUBLISHED

OCT 12, 2023

NANOVIRICIDES, INC. TO PRESENT AT THE PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY CONFERENCE IN BOSTON ON OCTOBER 16, 2023 AT 6:07PM ET

PUBLISHED

OCT 3, 2023

MULTI-BILLION DOLLAR TREATMENT MARKET FOR LUNG INFECTION THAT CAUSES OVER 200,000 HOSPITALIZATIONS ANNUALLY WITH ELDERLY, YOUNG AT MOST RISK HAS GAME-CHANGING NEW ENTRANT

PUBLISHED

SEP 27, 2023

MULTI-BILLION DOLLAR TREATMENT MARKET FOR LUNG INFECTION THAT CAUSES OVER 200,000 HOSPITALIZATIONS ANNUALLY WITH ELDERLY, YOUNG AT MOST RISK HAS GAME-CHANGING NEW ENTRANT

PUBLISHED

SEP 19, 2023

FIRST HUMAN CLINICAL TRIALS OF A POTENTIALLY “GAME-CHANGING BROAD SPECTRUM ANTIVIRAL” ARE PROGRESSING SUCCESSFULLY – DRUG COULD TREAT COVID, RSV AND MANY OTHER RESPIRATORY VIRUSES

PUBLISHED

AUG 31, 2023

NANOVIRICIDES PROGRESSING WELL WITH NEW COVID STUDY

PUBLISHED

AUG 21, 2023

THE PHASE 1A/1B HUMAN CLINICAL TRIAL OF NV-COV-2, THE COMPANY’S BROAD-SPECTRUM ANTIVIRAL DRUG, IS PROGRESSING SUCCESSFULLY, REPORTS NANOVIRICIDES

PUBLISHED

JUL 19, 2023

SARS-COV-2 IS NOT DONE YET — COULD THIS NEW DRUG IN CLINICAL TRIALS BE THE SAFEST OPTION FOR TREATING COVID-19?

PUBLISHED

JUL 13, 2023

NANOVIRICIDES TESTING ORAL GUMMY AND SYRUP COVID-19 TREATMENT – PROACTIVE RESEARCH ANALYST

PUBLISHED

JUL 11, 2023

NOVEL NANOMEDICINE PLATFORM WITH PIPELINE OF ANTIVIRALS GOES TO HUMAN TRIALS – WHAT OTHER VIRUSES COULD THIS COVID TREATMENT TARGET?

PUBLISHED

JUL 11, 2023

COMPANY’S BROAD-SPECTRUM ANTIVIRAL NV-387 HAS DEMONSTRATED EXCELLENT EFFECTIVENESS IN RSV IN A LETHAL LUNG DISEASE ANIMAL MODEL, REPORTS NANOVIRICIDES

PUBLISHED

JUL 6, 2023

NANOVIRICIDES INC. (NYSE AMERICAN: NNVC) BEGINS LONG-AWAITED CLINICAL TRIALS FOR ITS ANTI-VIRAL NANOMEDICINE NV-COV-2, ORAL, AMID CONTINUING NEED FOR COVID TREATMENT

PUBLISHED

JUL 6, 2023

CLINICAL TRIAL OF BROAD-SPECTRUM ANTIVIRAL DRUG NV-COV-2 IS PROGRESSING WELL, SAYS NANOVIRICIDES – NV-COV-2 IS POSITIONED TO FULFILL MANY UNMET MEDICAL NEEDS

PUBLISHED

JUN 29, 2023

NANOVIRICIDES TAKE BIG STEP FORWARD BEGINNING TRIALS ON ITS ANTIVIRAL DRUG NV-COV-2

PUBLISHED

JUN 29, 2023

NANOVIRICIDES ANNOUNCES THAT CLINICAL TRIALS OF ITS BROAD-SPECTRUM ANTIVIRAL DRUG NV-COV-2 HAVE BEGUN

PUBLISHED

MAY 31, 2023

NANOVIRICIDES, INC. TO PRESENT AT THE BIO INTERNATIONAL CONVENTION IN BOSTON ON JUNE 5TH, 2023 AT 3:15PM ET

MANAGEMENT TEAM

Anil R. Diwan, PhD

Executive Chairman, President

Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company’s 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company’s financing efforts since 2010.

Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, as well as informatics. He has won several NIH SBIR (small business innovation research) grant awards. Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. Dr. Diwan has over 25 years of Bio-Pharmaceutical R&D experience with over 20 years as an entrepreneur.

He has several patents issued internationally resulting from three fundamental international patent applications. Under Dr. Diwan’s leadership, NanoViricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels while robustly expanding the drug pipeline every year. Dr. Anil R. Diwan was recognized as “Researcher of the Year” by BusinessNewHaven, a Connecticut Area Business Journal, in 2014.

Ms. Meeta R. Vyas, MBA (Fin.), BS (Chem. Eng.)

interim Chief Financial Officer

Ms. Vyas is known as a strong leader with board level experience and successful achievements as a Senior Executive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to large size companies. Meeta has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed US corporation, Signature Brands, Inc., best known for “Mr. Coffee” and “Health-O-Meter” brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in a return to profitability and growth within a short period of time. Later, as the CEO of the World-Wide Fund for Nature – India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (GE). Also at GE, Ms. Vyas ran GE Appliances’ Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Meeta is married to NanoViricides, Inc. President and Chairman Anil R. Diwan.

Ms. Vyas holds a MBA in Finance from Columbia University’s Graduate School of Business, and a BS in Chemical Engineering from the Massachusetts Institute of Technology.

NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.

Randall W. Barton, PhD.

Chief Scientific Officer – Consulting

Dr. Barton has experience in drug discovery and development of both small molecule and biological drug candidates in virology, immunology, inflammation, and cardiovascular diseases in the pharmaceutical and biotech industry as well as academic research and teaching experience. Most recently, he was Vice-President of Drug Discovery at A&G Pharmaceuticals, a biologics and diagnostics company. He retired at the Director level after 20 years at Boehringer Ingelheim Pharmaceuticals. During his time at Boehringer Ingelheim he performed drug development pre-clinical studies on nevirapine (Viramune), a non-nucleoside inhibitor of HIV reverse transcriptase and an important HIV drug.

Prior to joining Boehringer Ingelheim, he was on the faculty at the University of Connecticut Medical School where he was the recipient of an NIH Career Development Award conducting research and teaching in immunology. Dr. Barton has authored over 80 scientific publications, and has been the principal investigator leading to 5 patents. He has a Ph.D. in biochemistry from the University of Tennessee at Oak Ridge National Laboratory and a B.A. from Indiana University.

Jayant Tatake, PhD.

Vice President, R&D

Jay Tatake is an organic chemist with over 25 years of experience in Research and Process Development of fine chemicals. His experience encompasses production scale-up, and large scale manufacture of raw materials for pharmaceuticals. Before joining NanoViricides, Inc., he was Assistant Director of Analytical R&D at Interpharm, Inc. Prior to that, he was Director of Analytical Services at Pharmax Group, Inc. Dr. Tatake has several years experience in Analytical methods development and Quality Control in cGMP environment. His experience includes bio-analytical methods development. Prior to Pharmax Group, he was in the Pharmacology Department, University of Connecticut Health Center, where he synthesized and developed novel bio-conjugates for bio-diagnostics applications.

Jay has a Ph.D. from Department of Chemical Technology, University of Bombay. He is a member of American Chemical Society (ACS). He has published several papers in leading journals and is a co-inventor of several patents.


SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY AMPLIFYIR INC FOR A ONE DAY NNVC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(NYSE American: MAIA) Profile

OUR NEW PROFILE IS:   (NYSE AMERICAN: MAIA)

MAIA BIOTECHNOLOGY RECENTLY ANNOUNCES SHARE REPURCHASE PROGRAM 

MAIA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR THIO, A FIRST-IN-CLASS TELOMERE TARGETING AGENT FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER

FDA GRANTS ORPHAN DRUG DESIGNATION TO MAIA BIOTECHNOLOGY FOR THIO AS A TREATMENT FOR GLIOBLASTOMA

READ THE INVESTOR PRESENTATION HERE

______________________________________

Hello Everyone,

We have a new NYSE profile for today’s session.

This could be a hidden gem with a major catalyst driving an intense reversal off of the 52 week low that it just recently hit.

The company released major news this morning that you should look into and research.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a first-in-class cancer telomere targeting agent in clinical development for the treatment of Non-Small Cell Lung Cancer (NSCLC) patients with telomerase-positive cancer cells.

*****BREAKING NEWS JUST RELEASED THIS MORNING*****

FDA GRANTS ORPHAN DRUG DESIGNATION TO MAIA BIOTECHNOLOGY FOR THIO AS A TREATMENT FOR GLIOBLASTOMA

  • Third orphan drug designation (ODD) granted to THIO by the FDA; drug also holds ODDs for hepatocellular carcinoma and small cell lung cancer
  • Benefits include 7 years of U.S. market exclusivity after drug approval and tax credits for qualified clinical testing
  • Expected glioblastoma market growth from $2.2 billion to $3.2 billion globally in the next three years

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, announced today that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation to its lead asset THIO, a cancer telomere-targeting agent, for the treatment of glioblastoma. This is the third orphan drug designation granted to THIO, following the receipt of orphan drug designations for hepatocellular carcinoma (HCC) and small cell lung cancer (SCLC) in 2022.

“We are pleased to receive a third orphan drug designation for THIO, further highlighting FDA’s recognition of THIO’s potential in the treatment of multiple cancer indications, including rare ones such as glioblastoma,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer. “Each year, globally, more than 300,000 people are diagnosed with brain tumors, of which, 25,000 are in the United States. Glioblastoma represents the majority of these cases in the U.S., with 15,000 new patients diagnosed and more than 10,000 deaths yearly, making it an orphan indication. Given this prevalence there is significant room for growth in the $2.2 billion glioblastoma market, which is expected to reach $3.2 billion globally in the next three years.1 We consider this ODD an important milestone for our development strategy and for glioblastoma patients who could benefit from a potentially revolutionary therapy.”

“In the data presented to the FDA, THIO successfully penetrated the blood brain barrier (BBB) in syngeneic and humanized mouse models of telomerase-expressing brain cancers. Treatment with THIO resulted in potent anticancer activity and significant expansion of the animal lifespan for several difficult to treat cell lines and xenograft mouse models,” added Sergei Gryaznov, Ph.D., MAIA’s Chief Scientific Officer. “These results stem from THIO’s remarkable mechanism of action and its BBB penetrating property that allows for direct targeting of brain tumors in vivo and potentially in glioblastoma patients.”

“Glioblastoma is the most aggressive and most common type of cancer that originates in the brain. With very limited treatment options available, glioblastoma patients have exceptionally short survival durations, and only 7% remain alive five years after being diagnosed with the condition,”2 said Mihail Obrocea, MD, MAIA’s Chief Medical Officer. “We are optimistic about our telomere-targeting agent’s ability to provide clinical benefit in patients with glioblastoma, and we look forward to studying THIO for the treatment of this highly unmet medical indication in a future trial.”

Enrollment is ongoing in a Phase 2 trial of THIO, THIO-101, evaluating the drug candidate in patients with advanced non-small cell lung cancer (NSCLC). THIO is the only direct telomere targeting agent currently in clinical development.

About Orphan Drug Designation

The FDA’s Orphan Drug Act of 1983 was designed to incentivize the development of therapies that demonstrate promise for the treatment of rare (orphan) diseases or conditions. A disease is classified as “rare” if it affects fewer than 200,000 people total in the U.S., or if the cost of developing a drug and making it available in the U.S. for such diseases will exceed any potential profits from its sale due to the small target population size. The FDA’s ODD program provides multiple incentives to make orphan drug development more financially possible for companies to pursue, such as up to seven years of market exclusivity for the approved orphan drug, up to 20 years of 25% federal tax credit for expenses incurred in conducting clinical research within the U.S. and waiver of Prescription Drug User Fee Act (PDUFA) fees for orphan drugs, a value of approximately $2.9 million in 2021.

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101, a Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate THIO’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of THIO administered prior to an anti-PD1 agent will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of THIO administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of THIO using Overall Response Rate (ORR) as the primary clinical endpoint. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

MAIA BIOTECHNOLOGY REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT DEVELOPMENT PROGRESS FOR ANTICANCER ASSET THIO

  • Substantial THIO program progress including unprecedented disease control rate (DCR) of 100% in second-line non-small cell lung cancer (NSCLC)
  • Key THIO findings in gliomas, pediatric brain cancer, and second generation THIO-derived cancer therapies
  • Strong pace of enrollment in THIO-101 Phase 2 trial exceeds average enrollment pace in similar NSCLC trials

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, today reported financial results for the third quarter ended September 30, 2023 and key operational updates.

“Our successful and productive third quarter was punctuated by the outstanding data on our lead asset THIO that we recently revealed, and an accelerating pace of enrollment in our THIO-101 Phase 2 trial,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer. “We are expanding our trial in Europe, and with the FDA’s recent clearance for THIO studies in the U.S. as part of THIO-101, we have reached an essential milestone in the clinical development of THIO. Preliminary efficacy data from the trial is excellent and includes an unprecedented disease control rate (DCR) of 100% in second-line NSCLC treatment, far surpassing the standard of care DCR of 53-64%. We achieved the pre-determined statistical requirements to proceed to the next stage of the trial earlier than expected, and we look forward to sharing our continuing progress in the coming months and into 2024.”

Third Quarter Business Highlights and Recent Developments

THIO Program:

Announced 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data: 100% preliminary DCR was observed in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatment. DCRs across all dose levels met the pre-determined statistical requirements earlier than expected to proceed to next stage of the THIO-101 Phase 2 trial.

Highly Potent Anticancer Activity in Gliomas: MAIA’slead asset THIO showed highly potent anticancer activity in models of glioma, an aggressive type of brain tumor that originates from glial cells and is among the most difficult-to-treat cancers. As a monotherapy, THIO demonstrated efficacy in multiple glioma cell lines that had acquired resistance to the current state-of-the-art care temozolomide (TMZ).

THIO as Potential Therapy for Pediatric Brain Cancer: Study data showed THIO’s potent anticancer activity in diffuse intrinsic pontine glioma (DIPG), one of the most aggressive tumors affecting the central nervous system in children. The treatment resulted in noticeably increased tumor sensitivity to immune or ionizing radiation therapies.

Higher Anticancer Potency of Next Generation THIO Conjugates: Positive Investigational New Drug-enabling study data on telomere-targeting agents derived from lipid-modified THIO molecules warrant further in vivo in-depth investigation of THIO-like agents as second generation cancer therapies.

THIO-101 Phase 2 Clinical Trial

U.S. FDA Clearance of THIO IND Application: TheU.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application enabling THIO to be evaluated in the U.S. as part of THIO-101, the Company’s ongoing global phase 2 clinical study in patients with advanced non-small cell lung cancer (NSCLC). THIO is being tested in sequential combination with a checkpoint inhibitor (CPI) to evaluate anti-tumor activity and immune response in NSCLC patients.

Strong Pace of Enrollment in THIO-101: 49 patients have been dosed to date at a pace of enrollment that is currently exceeding the average enrollment pace in similar NSCLC trials. Out of the 49 patients dosed, 37 have already completed at least one post baseline assessment.

Continuing Positive Preliminary Survival Data: The first 2 subjects dosed on trial (both receiving 3rd line of treatment) reported long term survival of 14.6 and 12.5 months, respectively, at the latest post baseline assessment with no new anti-cancer treatment initiated. Follow up was ongoing for the first subject at the time of data cut-off.

Third Quarter 2023 Financial Results

Cash Position: Cash totaled approximately $6.1 million as of September 30, 2023, compared to $10.9 million in cash as of December 31, 2022.

Research and Development (R&D) Expenses: R&D expenses were approximately $2.6 million for the quarter ended September 30, 2023, compared to approximately $2.3 million for quarter ended September 30, 2022. The increase was primarily related to an increase in scientific research expenses.

General and Administrative (G&A) Expenses: G&A expenses were approximately $2.4 million for the quarter ended September 30, 2023, compared to approximately $1.7 million for the quarter ended September 30, 2022. The increase for the quarter was primarily related to an increase in professional fees related to the write-off of deferred offering costs and an increase in investor relations costs.

Other Income, Net: Other income was approximately $0.08 million for the quarter ended September 30, 2023, compared to other income, net of $0.19 million for the quarter ended September 30, 2022, primarily related to a change in the fair value of warrant liability.

Net Loss: Net loss was approximately $4.9 million, or $0.36 per share, for the quarter ended September 30, 2023, as compared to net loss of approximately $4.9 million, or $0.48 per share, for the quarter ended September 30, 2022. Weighted average shares outstanding were 13,675,802 in the third quarter of 2023, compared to 10,165,622 in the third quarter of 2022.

For additional information on the Company’s financial results for the quarter ended September 30, 2023, please refer to the Form 10-Q filed with the SEC.

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101, Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate THIO’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of THIO administered prior to an anti-PD-1 agent will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of THIO administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of THIO using Overall Response Rate (ORR) as the primary clinical endpoint. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

MAIA BIOTECHNOLOGY REVEALS NEW DATA SHOWING THIO’S POTENT ANTICANCER ACTIVITY IN AGGRESSIVE PEDIATRIC BRAIN CANCER

OCT 12, 2023 9:20AM EDT

Treatment demonstrates decreased cancer cell proliferation and increased tumor sensitivity to ionizing radiation

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, announced that study data shows THIO’s potent anticancer activity in Diffuse Intrinsic Pontine Glioma (DIPG), one of the most aggressive tumors affecting the central nervous system in children.

The data was recently presented at the Society for Neuro-Oncology’s 2023 Pediatric Neuro-Oncology Research Conference and published in the Neuro-Oncology journal (Volume 25, Issue Supplement_1, June 2023, Page i13). The study evaluated THIO as a potential treatment for DIPG based on inducing direct telomeric DNA damage mediated cancer cell death and activating antitumor immunity in DIPG through the intracellular cGAS/STING pathway, which resulted in noticeably increased tumor sensitivity to immune or ionizing radiation therapies.

Radiotherapy is the only standard of care treatment option for DIPG, yet it is rarely curative. In recent years, several immunotherapy strategies have emerged as potential treatments for DIPG. However, the low mutational burden and rare infiltration of T lymphocytes renders these tumors immunologically “cold” and, therefore, poses challenges for general immunotherapy.

“We have shown that THIO treatment sensitized DIPG cells to ionizing radiation (IR), leading to a significant decrease in DIPG cell proliferation in vitro and in vivo models,” said MAIA’s Chief Scientific Officer Sergei Gryaznov, Ph.D. “These encouraging preclinical studies may support further potential preclinical and clinical development of THIO to be used in combination with IR to treat children with high-risk pediatric brain tumors.”

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer(NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

MAIA BIOTECHNOLOGY ANNOUNCES SHARE REPURCHASE PROGRAM

September 28, 2023 8:01am EDT

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $800,000 of its Class A common stock through September 2024.

“This share repurchase program demonstrates the confidence we have in our market opportunity and our strategy to invest for long-term growth, which we believe is not reflected in the current market valuation,” said Vlad Vitoc, MAIA’s Chief Executive Officer. “By establishing a repurchase plan, we add another tool to our arsenal that can assist with our future financing efforts, enable us to unlock more of the long-term opportunity we see ahead, and drive sustainable value for all stakeholders.”

With a share repurchase program, MAIA may repurchase shares from time to time through various methods, including in open market transactions, in privately negotiated transactions or otherwise, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, in compliance with applicable state and federal securities laws. The timing, as well as the number and value of shares repurchased under the program, will be determined by the Company at its discretion and will depend on a variety of factors, including our assessment of the intrinsic value of the Company’s common stock, the market price of the Company’s common stock, general market and economic conditions, available liquidity, compliance with the Company’s debt and other agreements, applicable legal requirements, the nature of other investment opportunities available to the Company, and other considerations. The Company is not obligated to purchase any shares under the repurchase program, and the program may be suspended, modified, or discontinued at any time without prior notice. The Company expects to fund the repurchases by using cash on hand and expected free cash flow to be generated in the future.

Significant Market Opportunity

  • Cancer is the most dominant of the age-related disease categories and has life altering impacts in the lives of patients and their close ones
  • The number oF people aged 80 years or older is expectedtotriplebetween 2020 and 2050 to reach 426 million
  • Approximately40%ofpeoplealivetodayareprojectedtobediagnosed with a cancer type in their lifetime, and 20% will die of it
  • NSCLC is the leading tumor type: Mortality 1.7M / Sales $32B (2022)
  • CRCissecond:Mortality1M/Sales$20B(2022)

Clinical Programs

THIO-101: Ph 2 trial THIO + LIBTAYO® (cemiplimab) – enrolling (35 patients dosed to date)

  • Go-to-market trial in second line NSCLC
  • Objectives: select most efficacious dose and expand into pivotal trial
  • Started in 2022 in Australia & Europe; to include US in 2023
  • Regeneron clinical supply agreement for Libtayo®
  • File for accelerated approval in 2025
  • Part A (Safety Lead-in) Complete: No dose-limiting toxicities (DLTs), No Serious Adverse Events (SAE) or Serious Unexpected Suspected Adverse Reactions (SUSAR); Safety profile substantially better than current Standard of Care (SoC)
  • Preliminary Survival: first 2 patients dosed in Part A continue to be alive, 12.2 and 11.5 months from treatment initiation; progression free after last dose, 10.2 and 8.5 months respectively, with no new treatment; in real-world clinical practice, observed survival in similar heavily pretreated patients is 3-4 months; weeks without therapy
  • Disease Control Rate: 82%; subjects with 1+ post-baseline response assessment (n=11, 06/23/23); DCR for SoC in third line: 25-35%
  • Part B (efficacy/dose selection) initiated THIO-102: Ph 2 trial THIO + CPIs
  • Go-to-market trial in late line of therapy in multiple tumor. types: Colorectal Cancer (CRC), Hepatocellular Carcinoma (HCC, 90% of primary type of liver cancers), and Solid Tumors of any type (ST)
  • 3 umbrellas in each: THIO + Libtayo (REGN); Keytruda (MRK); Tecentriq (Genentech/Roche)
  • Objectives: select most efficacious combination by tumor type and expand into pivotal trials (9+ possible market entry indications)
  • Start in 2023, to include US, Europe, Asia, etc.
  • File for accelerated approvals in 2026 and beyond THIO-103: Ph 2/3 trial of THIO + CPIs
  • First line NSCLC and SCLC
  • Expand to Breast, Prostate, Pancreatic, Ovarian, Gastric Cancer, etc.

THIO is a Unique Direct Telomere Targeting Agent
• Potential to be used in combination with other anticancer and immune therapies
• Dual, novel mechanism of action: telomere

targeting + immunogenic
• FDA awarded THIO 2 Orphan Drug

Designations: HCC and SCLC!
• Excellent efficacy: achieved complete and durable responses in HCC in vivo models (peer-reviewed published study)

MAIA BIOTECHNOLOGY ANNOUNCES POTENT ANTICANCER ACTIVITY OF THIO IN GLIOMAS

October 10, 2023 8:01 am EDT   CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced that its lead asset THIO showed highly potent anticancer activity in gliomas, an aggressive type of brain tumor that originates from glial cells. THIO’s novel dual mechanism of action – direct telomere targeting and immune system activation, has previously demonstrated similar efficacy in multiple types of telomerase-active tumors.

THIO was evaluated in various in vitro and in vivo models of gliomas. The results demonstrate the promising therapeutic role of THIO for the treatment of primary and temozolomide-resistant recurrent gliomas through specific telomerase-mediated induction of telomeric DNA damage in glioma cells

“High grade adult gliomas are among the most difficult-to-treat cancers, with less-than-desirable clinical outcomes. These encouraging results further highlight THIO’s excellent anti-cancer activity across several cancer indications,” said Vlad Vitoc, M.D., MAIA’s Chief Executive Officer. “We look forward to evaluate THIO as a treatment for brain cancer in clinical setting.”

“THIO was effective in the majority of human and mouse glioma cell lines with no apparent toxicity against normal astrocytes. As a monotherapy, THIO demonstrated efficacy in multiple glioma cell lines that had acquired resistance to the current state-of-the art care temozolomide (TMZ). THIO induced apoptosis in several human glioma cell lines that grow as three-dimensional tumor mass-mimicking neurospheres,” said MAIA’s Chief Scientific Officer Sergei Gryaznov, Ph.D. “Additionally, THIO produced telomeric DNA damage responses not only in glioma cell lines, but also in diverse human-derived tumor specimens (PDXs). In vivo, THIO significantly decreased tumor proliferation in glioblastoma xenografts and a PDX model of glioblastoma.”

The reviewed results were published in: Clin Cancer Res (2021) 27 (24): 6800–6814.

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

Partnership with Regeneron

• Clinical supply agreement: Regeneron provides Libtayo® for THIO-101

• Equivalent to $32M non-dilutive participation (largest financing move to date)

• Potentially expand existing relationship and target new companies

Strong and Growing IP Portfolio

• Potential for receiving NCE marketing exclusivity; 5 patents issued, 12 patent applications pending

Next Generation Potential Telomere Targeting Therapeutics
• 84 new molecules engineered in last 12

months; Same mechanism of action as THIO • MAIA-2021-020, MAIA-2022-012 and

MAIA-2021-029 significantly moreCefficacious
• Follow THIO to commercial stage within 4-5 years

NEWS

Nov 10, 2023 7:01am EST

FDA GRANTS ORPHAN DRUG DESIGNATION TO MAIA BIOTECHNOLOGY FOR THIO AS A TREATMENT FOR GLIOBLASTOMA

Nov 07, 2023 8:15am EST

MAIA BIOTECHNOLOGY REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT DEVELOPMENT PROGRESS FOR ANTICANCER ASSET THIO

Oct 30, 2023 8:41am EDT

MAIA BIOTECHNOLOGY REVEALS HIGHER ANTICANCER POTENCY OF TELOMERE-TARGETING COMPOUNDS DERIVED FROM THIO

Oct 24, 2023 8:00am EDT

MAIA BIOTECHNOLOGY ANNOUNCES 100% DISEASE CONTROL IN SECOND-LINE NON-SMALL CELL LUNG CANCER DEMONSTRATING IMPRESSIVE POSITIVE PRELIMINARY EFFICACY DATA FOR ONGOING THIO-101 PHASE 2 TRIAL

Oct 19, 2023 8:35am EDT

MAIA BIOTECHNOLOGY TO PRESENT PRELIMINARY SAFETY AND EFFICACY DATA FROM THIO-101 PHASE 2 CLINICAL TRIAL AT EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS 2023

Oct 17, 2023 8:01am EDT

MAIA BIOTECHNOLOGY TO PRESENT LATEST FINDINGS FOR SECOND GENERATION THIO PROGRAM AT TURKISH BIOCHEMICAL SOCIETY’S INTERNATIONAL BIOCHEMISTRY CONGRESS 2023

Oct 12, 2023 9:20am EDT

MAIA BIOTECHNOLOGY REVEALS NEW DATA SHOWING THIO’S POTENT ANTICANCER ACTIVITY IN AGGRESSIVE PEDIATRIC BRAIN CANCER

Oct 10, 2023 11:15am EDT

MAIA BIOTECHNOLOGY ACCELERATES ENROLLMENT IN THIO-101 PHASE II CLINICAL TRIAL AS EFFICACY IS OBSERVED IN DOSED PATIENTS

Oct 10, 2023 8:01am EDT

MAIA BIOTECHNOLOGY ANNOUNCES POTENT ANTICANCER ACTIVITY OF THIO IN GLIOMAS

Oct 03, 2023 8:01am EDT

MAIA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR THIO, A FIRST-IN-CLASS TELOMERE TARGETING AGENT FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER

Sep 28, 2023 8:01am EDT

MAIA BIOTECHNOLOGY ANNOUNCES SHARE REPURCHASE PROGRAM

Aug 08, 2023 8:00am EDT

MAIA BIOTECHNOLOGY REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES UPDATES FOR THIO-101 PHASE 2 TRIAL FOR NON-SMALL CELL LUNG CANCER

Jul 11, 2023 8:00am EDT

MAIA BIOTECHNOLOGY REPORTS UPDATES ON DISEASE CONTROL RATES FOR THIO-101 PHASE 2 TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER

Jul 10, 2023 8:00am EDT

MAIA BIOTECHNOLOGY REPORTS UPDATES ON PRELIMINARY SURVIVAL DATA FOR THIO-101 PHASE 2 TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER

Jun 20, 2023 8:00am EDT

MAIA BIOTECHNOLOGY ANNOUNCES UPDATES IN ENROLLMENT IN PHASE II CLINICAL TRIAL: THIO-101 HAS ENROLLED 29 PATIENTS

Jun 07, 2023 8:00am EDT

MAIA BIOTECHNOLOGY FILES SECOND PATENT FOR NEW TELOMERE-TARGETING MOLECULES PROGRAM

May 08, 2023 8:00am EDT

MAIA BIOTECHNOLOGY REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Apr 27, 2023 4:10pm EDT

MAIA BIOTECHNOLOGY, INC. ANNOUNCES CLOSING OF PUBLIC OFFERING

Apr 24, 2023 9:06pm EDT

MAIA BIOTECHNOLOGY, INC. ANNOUNCES PRICING OF PUBLIC OFFERING

Apr 20, 2023 8:00am EDT

MAIA BIOTECHNOLOGY REPORTS PRELIMINARY SURVIVAL DATA IN PART A OF THIO-101 PHASE 2 TRIAL FOR NON-SMALL CELL LUNG CANCER

MANAGEMENT TEAM

team

VLAD VITOC, MD, MBA

CHIEF EXECUTIVE OFFICER AND CHAIRMAN

Dr. Vitoc is our Chairman of Board, Chief Executive Officer, and President. Dr. Vitoc has a broad array of experience across commercial strategic analysis and planning and medical affairs, in which he has 20 years of experience. During that time, Dr. Vitoc has managed and supported over 20 early, launch, and mature stage compounds, which have included targeted therapies and immune therapies across more than 25 tumor types, including colorectal cancer, hepatocellular carcinoma, lung cancer, breast cancer, prostate cancer, and renal cell carcinoma. Vlad received an M.D. from the University of Medicine and Pharmacy “Iuliu Hatieganu”, Cluj-Napoca, Romania, and his M.B.A. from the University of South Carolina.

team

JOSEPH F. MCGUIRE

CHIEF FINANCIAL OFFICER

Mr. McGuire is our Chief Financial Officer, and he brings over 30 years of experience to MAIA, having served as Chief Financial Officer for several privately held and publicly traded companies in the healt

team

SERGEI M. GRYAZNOV, PHD

CHIEF SCIENTIFIC OFFICER

Dr. Gryaznov is our Chief Scientific Officer. Dr. Gryaznov is an internationally recognized scientist and expert in the areas of modern drug discovery and development, oncology, telomerase, immune-regulatory therapeutics, nucleosides, nucleotides, DNA and RNA analogues, lipid and other conjugates, small molecules, and nucleic acid based therapeutic agents. Dr. Gryaznov is the co-inventor of a novel telomere-by-telomerase-targeting therapeutic approach to potential cancer treatment and responsible for leading the research team that characterized THIO’s telomere targeting activity, our lead compound in development. Dr. Gryaznov obtained an M.S., with Honors, in Organic Chemistry and a Ph.D. in Chemistry of Natural Products from M.V. Lomonosov Moscow State University. Dr. Gryaznov also completed a post-doctoral fellowship program in Chemistry at Northwestern University in Evanston, IL.

team

MIHAIL OBROCEA, MD

CHIEF MEDICAL OFFICER

Mihail is a board-certified internist and hematologist/oncologist with over 25 years’ experience in drug development in both academia and pharmaceutical/biotechnology industry. His broad clinical drug development expertise in both hematology and oncology covers equally early and late-stage development of cell therapy, cancer vaccines, monoclonal antibodies, and small molecules. Mihail completed a residency program in internal medicine at Yale University followed by a fellowship program in hematology/oncology at Dartmouth with academic appointment as Instructor of Medicine in the division of Hematology & Oncology at Mary Hitchcock Medical Center and Geisel Medical School at Dartmouth.

He started his career in pharmaceutical industry at Pfizer Oncology leading the CD40 agonist and IGF-1R antibodies projects, which entered in early clinical trials. Subsequently he led the Medical Affairs Oncology group at MedImmune, Gaithersburg MD and later as VP, Clinical Development Oncology at MannKind Corp., Valencia, CA successfully brought into clinic two cancer vaccine programs. As a Global Project Lead for AbbVie Biotherapeutics in Redwood City, CA, he was responsible for the early clinical oncology monoclonal antibody programs and as Head, Medical Sciences at Pharmacyclics, Sunnyvale CA he took part in the commercial launch of ibrutinib (IMBRUVICA™) program in mantle cell lymphoma and chronic lymphocytic leukemia. As VP of Clinical and Medical Affairs at SFJ Pharmaceutical Group, a venture pharma company supported the medical and business operations of the Pfizer Oncology partnership on the Phase 3, pivotal trial which led to the FDA approval of Besponsa® (inotuzumab ozogamicin) in the R/R adult B-cell ALL.

Later as US Clinical Lead at Nanobiotix Corp, a biotechnology company based in Paris, France which develops nanotechnologies for use in radiation oncology, established the US clinical programs and was involved in the strategic business development, investor, and partner interaction. As a Program Lead at Juno Therapeutics Inc and later Celgene he had the US clinical oversight of 2 clinical trials including the registration Ph 3 trial in second line aggressive large B-cell lymphomas of BREYANZI® (lisocabtagene maralucel) an autologous CD19 targeted CAR T program approved in both US and EU in R/R large B-cell lymphoma. More recently, as Project and Clinical Lead at Atara Bio, a T-cell therapy company based in Thousand Oaks, CA he supported the pre-clinical and clinical development of the Atara’s allogeneic CAR T platform for both lymphoma and solid tumor indications.

Mihail published in oncology peer-reviewed literature and is co-author of a couple of books related to cancer vaccines and immunology as well as he holds several patents in the field of biotechnology.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY SICA MEDIA LLC FOR A ONE DAY MAIA AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(Nasdaq: IVP) Profile

OUR NEW PROFILE IS: (NASDAQ: IVP)

____________________

REVENUE RUN RATE ~$19M, 13LOCATIONS ACROSS 9 STATES, ~$3.5M IN REI

3 NEW LOCATIONS UNDER LOI WHICH WILL BRING AN ADDITION $6M OF ANNUAL REVENUE AND $2M IN REI

IN THE LAST 2 MONTHS THE COMPANY HAS PROPOSED ACQUISITIONS TO ADD 3 NEW ANIMAL HOSPITALS TO THEIR CURRENT NETWORK OF 13 FACILITIES

IVP HAS A TINY FLOAT UNDER 7 MILLION RIGHT NOW

READ THE INVESTOR PRESENTATION HERE

__________________________________________

Hello Everyone,

We have been able to profile so significant movers over the past month.  There have been a handful of low float bottom bouncers.  Our profile from last Wednesday that we released at 2 pm has closed green 5 sessions in a row and hit .98 yesterday, up almost 100% from the .50 level from last Wednesday afternoon.

There is another company that we want to bring to your attention immediately.

This one closed green 4 sessions in a row heading into today and appears to be reversing off of bottom.

Pull up IVP Immediately.

The U.S. pet industry generated $103B in 2020. In 2017 there were 28,000+ pet hospitals in the U.S.

Inspire is an owner of general practice veterinary clinics in the United States. Inspire acquires practices, and, in many cases real estate, and then works with teams on a long- term basis to improve and maintain hospital operations, grow revenues and maximize earnings. As the Company expands, it is adding new services hospitals, including mixed animal facilities, critical and emergency care, and other specialty services such as equine, in one location.

THIS ONE JUST BOTTOM OUT AT .58 AND HAS BEEN STEADILY CLIMBING BACK TOWARDS THAT CRUCIAL 1 DOLLAR LEVEL SINCE THEN.

THE NEAR FUTURE

The 5-year plan includes a 10 location per year run rate for acquisitions and a public event within that timeframe which allows Inspire to share equity with all associates working in its locations.

DIFFERENTIATORS

Key relationships from the acquisition process through operations and the unique position of a publicly-traded veterinary services organization, provide us advantages in growth capability,

WHAT IS INSPIRE, WHAT IS THE 5 YEAR PLAN? 

Key relationships from the acquisition process through operations and the unique position of a publicly-traded veterinary services organization, provide us advantages in growth capability, efficiency, and employee retention.

INSPIRE VETERINARY PARTNERS, INC. ANNOUNCES NON-BINDING LETTER OF INTENT TO ACQUIRE ANIMAL HOSPITAL AND ENTER THE STATE OF PENNSYLVANIA

  • Proposed acquisition to add one new animal hospital to Inspire’s network of 13 animal hospitals.
  • Expansion into a new state, Pennsylvania.
  • Pipeline of attractive acquisitions of animal hospitals remains active; Future acquisitions to be announced in 2023.
  • The transaction is anticipated to close October 2023.

VIRGINIA BEACH, VA / ACCESSWIRE / September 21, 2023 / Inspire Veterinary Partners, Inc. (Nasdaq:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the US, today announced that it has entered into a non-binding letter of intent to acquire a 100% ownership interest in one animal hospital located in Pennsylvania, a first for Inspire and follows its recently announced LOI for 2 animal hospitals in Oregon.

Inspire expects to acquire real estate associated with the purchase. The proposed acquisition is subject to customary closing conditions and is currently expected to be completed as early as the third quarter of 2023.

Inspire’s due diligence review of the target acquisition has already commenced, and upon satisfactory completion, the Company intends to proceed towards executing a definitive acquisition agreement and closing the transaction as soon as all closing conditions are met.

Kimball Carr, Chairman, Chair, President & Chief Executive Officer of Inspire, stated, “We’re excited to continue our growth nationwide and for Pennsylvania to be added to the list of states at which Inspire and our hospital teams serve clients and pets each day. We look forward to more anticipated growth in the great Commonwealth of Pennsylvania and the Eastern U.S.”

The letter of intent is non-binding and subject to additional diligence and other factors, and as such, there can be no assurance that the Company will enter into a definitive acquisition agreement or that the terms of any such agreement will not change, or that the proposed acquisition will be consummated in the third quarter of 2023 or at all.

INSPIRE VETERINARY PARTNERS, INC. ANNOUNCES NON-BINDING LETTER OF INTENT TO ACQUIRE TWO ANIMAL HOSPITALS AND ENTER THE STATE OF OREGON

  • Proposed acquisition to add 2 animal hospitals to Inspire’s network of 13 animal hospitals
  • Expansion into a new state, Oregon, constituting our first emergency veterinary clinic and first rehabilitation hospital
  • The transaction is expected to close as early as the third quarter of 2023
  • Opportunity to continue to acquire individual animal hospitals remains strong

VIRGINIA BEACH, VA / ACCESSWIRE / September 1, 2023 / Inspire Veterinary Partners, Inc. (Nasdaq:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the US, today announced that it has entered into a non-binding letter of intent to acquire a 100% ownership interest in two animal hospitals. The hospitals would represent expansion by Inspire into a new state, Oregon, and the Company’s first emergency veterinary clinic and first rehabilitation hospital under its network.

Inspire expects to acquire real estate associated with the purchases. The proposed acquisitions are subject to customary closing conditions and are currently expected to be completed as early as the third quarter of 2023.

Inspire’s due diligence review of the target acquisition has already commenced, and upon satisfactory completion, the Company intends to proceed towards executing a definitive acquisition agreement and closing the transaction as soon as all closing conditions are met.

Kimball Carr, Chairman, Chair, President & Chief Executive Officer of Inspire, stated, “We are very excited for this opportunity to acquire two new hospital teams who share our mutual belief that we can make a difference in the veterinary profession and serve even more clients and pets, for the first time, in the great state of Oregon.”

The letter of intent is non-binding and subject to additional diligence and other factors, and as such, there can be no assurance that the Company will enter into a definitive acquisition agreement or that the terms of any such agreement will not change, or that the proposed acquisition will be consummated in the third quarter of 2023 or at all.

NEWS

PUBLISHED

SEP 26, 2023

INSPIRE VETERINARY PARTNERS, INC. TO PRESENT AT THE EMERGING GROWTH CONFERENCE, THURSDAY, OCTOBER 5, 2023

PUBLISHED

SEP 21, 2023

INSPIRE VETERINARY PARTNERS, INC. ANNOUNCES NON-BINDING LETTER OF INTENT TO ACQUIRE ANIMAL HOSPITAL AND ENTER THE STATE OF PENNSYLVANIA

PUBLISHED

SEP 13, 2023

INSPIRE VETERINARY PARTNERS, INC. ANNOUNCES LEADERSHIP APPOINTMENTS ENHANCING OPERATIONAL AND FINANCIAL TALENT TO SUPPORT FUTURE GROWTH

PUBLISHED

SEP 1, 2023

INSPIRE VETERINARY PARTNERS, INC. ANNOUNCES NON-BINDING LETTER OF INTENT TO ACQUIRE TWO ANIMAL HOSPITALS AND ENTER THE STATE OF OREGON

PUBLISHED

AUG 31, 2023

INSPIRE VETERINARY PARTNERS, INC. ANNOUNCES CLOSING OF $6.4 MILLION INITIAL PUBLIC OFFERING

CHECK OUT THE INVESTOR PRESENTATION HERE:

https://view.officeapps.live.com/op/embed.aspx?src=https%3A%2F%2Fwww%2Einspirevet%2Ecom%3A443%2Fprivate%2F64ef74e495299&wdAr=1.7777777777777777&Embed=1

MANAGEMENT TEAM

KIMBALL CARR

Chairman, President & CEO

STITH KEISER

Vice Chairman, Chief Operating Officer

DR. ALEXANDRA QUARTI

Vice President of Medical Operations

ZANDER CARRAWAY

Director of Acquisitions

JULIE KEEL

Director of Hospital and Office Support

LAUREN SILVA

Manager of Hospital Transitions and Support

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY AMPLIFYIR INC FOR A ONE DAY IVP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

BSGM Nasdaq Profile

BioSig Technologies, Inc.

_______

OUR NEW PROFILE IS:   (NASDAQ: BSGM)

BIOSIG’S NEW PURE EP™ SUBSCRIPTION MODEL ADOPTED BY MAYO CLINIC-PHOENIX FOR WORLD-CLASS CARDIAC CARE

OVER 3,000 PROCEDURES HAVE BEEN PERFORMED USING THE PURE EP™ SYSTEM WITH MORE THAN 80 PHYSICIANS AT 21 HOSPITALS ACROSS THE UNITED STATES

SUBSTANTIAL AND GROWING IP PATENT PORTFOLIO

IN 2022 THE CEO PURCHASED OVER 200K SHARES

BIOSIG AI SCIENCES RECEIVES $2.2 MILLION IN SEED FUNDING TO ADVANCE DEVELOPMENT OF ARTIFICIAL INTELLIGENCE APPLICATIONS

__________________

GET THE INVESTOR PRESENTATION HERE

__________________________________

Hello Everyone,

We have another profile that we want you to take a look at before the week is over.

If you have been a member for a while then you will certainly remember this one.

We profiled this one last year back in early December when it was sitting under .50, exactly where it is right now.  By Mid February this one tapped 1.46 for a 200% move in just 2 months.  BSGM certainly has a history of making big moves on positive news.

Pull up BSGM immediately before the weekend.  

BSGM is an advanced digital signal processing technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. The Company operates within the rapidly growing electrophysiology (EP) marketplace – a market projected to reach $16B by 2028 with a 11.2% growth rate.

BioSig’s first product, the PURE EPTM System, is an FDA 510(k) cleared non-invasive class II device, that provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.

Having recently commenced PURE EPTM’s national commerical launch, the technology is already an integral part of many well-respected healthcare systems, including Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute. To date, physicians have completed approximately 3000 patient cases with the PURE EPTM System.

ACHIEVEMENTS

  • On January 10, 2023, we announced that Bellin Health entered into an agreement to acquire a PURE EP™ System. Through a formal evaluation, Bellin reported that clear cardiac signals positively impacted procedural efficiency resulting in cost savings per procedure.
  • Over 3,000 procedures have been performed using the PURE EP™ System with more than 80 physicians at 21 hospitals across the United States.
  • The PURE EP™ System was featured in an abstract presentation at the 15th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in Singapore. Results from the randomized study revealed the PURE EP™ System’s potential to promote shorter procedural times and higher cost savings during catheter ablation procedures.
  • BioSig’s PURE EP™ System was highlighted in a peer-reviewed case report by the Journal of Atrial Fibrillation & Electrophysiology (JAFIB-EP). This clinical abstract detailed the value of PURE EP™ and its groundbreaking High Frequency Algorithm (HFA) during pulmonary vein isolation.
  • A Master Research Agreement was signed with the Cleveland Clinic to explore expanded applications for its digital signal processing technology.
  • A purchase agreement was signed with San Antonio Methodist Hospital.
  • Launched PURE EP™ software Version 6 with ACCUVIZ™ Module highlighting the proprietary High Frequency Algorithm (HFA), a novel feature that identifies the key frequency components of cardiac data that can be difficult to identify within the traditional waveform presentation.
  • Cleveland Clinic, a leading Medical Center of Excellence, agreed to evaluate the PURE EP System, and a short time later requested a second system for evaluation.
  • A purchase agreement was signed with Kansas City Heart Rhythm Institute at Overland Park Regional Medical Center.
  • The PURE EP™ System was featured at numerous conferences including Kansas City Heart Rhythm Symposium 2022, the 17th Edition Venice Arrhythmias 2022 Congress, and EPLive 2022.

INVESTMENT HIGHLIGHTS

  • Disruptive and novel technology
  • Our technology saves procedural time and improves workflow efficiency in an environment where the technology has not changed meaningfully in 25+ years.
  • Substantial and growing global market
  • Global EP market is growing by 11.2% and expected to reach $16B by 2028.
  • Strong clinical data pipeline
  • Published/ongoing clinical studies supporting commercialization.
  • First customers are industry leaders
  • World-renowned Medical Centers of Excellence.
  • Flexible pricing model
  • Supports recurring revenue and continuous innovation.
  • Fortune 500 commercial team
  • Proven track-record of generating sales growth.
  • Well-protected IP portfolio
  • ’59 Worldwide fundamental patents granted/allowed

BIOSIG’S NEW PURE EP™ SUBSCRIPTION MODEL ADOPTED BY MAYO CLINIC-PHOENIX FOR WORLD-CLASS CARDIAC CARE

PURE EP™ SUBSCRIBER COMMUNITY NOW INCLUDES TWO OF TOP THREE U.S. HEALTH SYSTEMS IN CARDIOLOGY: MAYO CLINIC-PHOENIX AND CLEVELAND CLINIC

Westport, CT, Nov. 02, 2023 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, announced today that Mayo Clinic-Phoenix—an existing user of the PURE EP™ Platform—has upgraded to the Platform’s subscription model to gain immediate access to the Company’s latest technological advancements in cardiac arrhythmia identification.

Harnessing the power of automation, PURE EP™’s latest software features debut unique algorithms that unlock signal data for electrophysiologists conducting even the most challenging ablation procedures.

  • Automatic Tachycardia Characterization (ATC) alerts electrophysiologists to heart conduction patterns that may be difficult to detect with the naked eye or that might warrant further evaluation.
  • Near-Field Tracking (NFT) monitors changes in the local unipolar electrogram to provide real-time tissue feedback that assists electrophysiologists as they make their final determinations between healthy and scarred tissue for lesion placement during an ablation.

“Our commitment to innovation and delivering exceptional patient care drives our ongoing collaboration with BioSig,” said Hicham El Masry, M.D., FHRS, Cardiac Electrophysiologist at Mayo Clinic-Phoenix. “The integration of PURE EP™’s advanced software features further reinforces our dedication to providing the best possible healthcare solutions for our patients. We look forward to the positive impact this partnership will have on our cardiac procedures.”

Mayo Clinic-Phoenix is ranked as the number one hospital in Arizona, according to the U.S. News and World Report. Within the specialty of cardiology, heart, and vascular surgery, the institution is ranked in the top one percent of hospitals nationwide (33 out of 4,515 hospitals).1

With Mayo Clinic-Phoenix and Cleveland Clinic now part of the PURE EP™ subscriber community, two out of the top three ranked health systems in cardiology, heart, and vascular surgery have embraced PURE EP™.2

“We are thrilled to roll out our newest, most innovative software to one of our company’s longest standing partners. As we continue building out PURE EP™’s software suite, customers will have the flexibility to purchase and add enhancements that meet their needs,” commented Gray Fleming, Chief Commercial Officer of BioSig. “By removing the burden of ownership and maintenance, we’re putting the latest PURE EP™ developments in physician’s hands as they unfold—unlocking the full potential of the electrophysiology lab.”

Leveraging full-spectrum signal data has significantly reduced ablation procedure times. Initial evidence suggested potential savings of approximately $418.20 per procedure using PURE EP™’s clear signals.3 Recent independent research by Cleveland Clinic shows PURE EP™’s unique unipolar capabilities may cut procedure times by up to 66%.4With the global cardiac ablation market set to exceed $14.5 billion by 2032,5 PURE EP™ offers substantial cost savings and efficiency gains for hospitals, improving patient outcomes through shorter procedures.

With a comprehensive suite of tools available through the subscription model, the PURE EP™ Platform can deliver the latest developments in electrophysiology to physicians as they emerge, with the flexibility to add enhancements as desired. For more information on how PURE EP™ can enhance arrhythmia identification and laboratory workflows, visit BioSig.com.

About The PURE EP™ Platform

The PURE EP™ Platform serves physicians by enabling the real-time acquisition of raw cardiac signal data—absent of unnecessary noise or interference inherent in traditional approaches. By leveraging a first-of-its-kind combination of hardware and software, the PURE EP™ Platform is designed to deliver unprecedented intracardiac signal purity that pushes the boundaries of cardiac arrhythmia identification, diagnosis, and treatment.

In a blinded clinical study recently published in the Journal of Cardiovascular Electrophysiology,5electrophysiologists rated PURE EP™ as superior to conventional systems for 75.2% of signal samples, with 87% earning a rating of equivalent or superior. Data presented at Heart Rhythm Society 2023 demonstrated the PURE EP™ Platform’s capacity to facilitate ablations in a third of the usual time, reducing procedure time and improving workflow efficiencies, without sacrificing accuracy, precision, or efficacy.

The PURE EP™ Platform is currently in a national commercial launch and an integral part of well-respected healthcare systems, including Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute.

BIOSIG ADDS FIVE NEW PATENT AWARDS TO 100+ TOTAL PATENT PORTFOLIO COVERING DIGITAL SIGNAL PROCESSING TECHNOLOGY AND AI

IP PORTFOLIO INCLUDES U.S. AND WORLDWIDE UTILITY AND DESIGN PATENTS AND PENDING APPLICATIONS IN THE U.S., EUROPE, AND ASIA-PACIFIC

Westport, CT, Nov. 01, 2023 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, announced today that the U.S. Patent and Trademark Office has awarded several new utility patents covering the Company’s PURE EP™ digital signal processing technology.

Kenneth Londoner, Chairman and CEO of BioSig, commented, “We are pleased to add five  utility patent awards to our expanding intellectual property portfolio of more than 100 patents and patent applications in the U.S. and abroad. Our robust patent protection and well-constructed claims cover BioSig’s first mover advantage for our novel PURE EP™ Platform.”

New Patent Awards

U.S. Patent Application No. 16/543,061 was allowed on September 22, 2023 and is entitled “Systems and Methods To Display Cardiac Signals Based on a Signal Pattern.” The patent application describes and claims a computer method for viewing cardiac signals side by side and vertically stacked on top of each other as a pattern is matched to one of the cardiac signals.

U.S. Patent No. 11,737,699 granted on August 29, 2023 and is entitled “Systems and Methods for Performing Electrophysiology (EP) Signal Processing.” The patent describes and claims methods and systems for producing a clean unipolar signal.

U.S. Patent No. 11,737,701 granted on August 29, 2023 and is entitled “Methods, Systems and Media For Reconstructing Bioelectric Lead Placement.” The patent describes and claims methods and systems for reconstructing electrode placement on a patient using artificial intelligence.

U.S. Patent 11,617,529 granted on April 4, 2023 and is entitled “Apparatus and Methods for Removing a Large-Signal Voltage Offset from a Biomedical Signal.” The patent claims a method for processing an electrical signal having a large differential voltage offset.

U.S. Patent 11,617,530 granted on April 4, 2023 and is entitled “Apparatus and Methods for Removing a Large-Signal Voltage Offset from a Biomedical Signal.” The patent claims a system for the removal of noise in electrocardiogram (ECG) and intracardiac (IC) signals.

BioSig’s Total Patent Portfolio

  • 35 issued and allowed utility patents
  • 30 issued worldwide design patents
  • 23 U.S. and foreign utility patent applications pending covering various aspects of the PURE EP Platform
  • 1 allowed and 1 pending U.S. patent applications directed to artificial intelligence (AI)
  • Licenses to 11 patents and 9 additional worldwide utility patent applications pending from Mayo Foundation for Medical Education and Research

BIOSIG AI SCIENCES RECEIVES $2.2 MILLION IN SEED FUNDING TO ADVANCE DEVELOPMENT OF ARTIFICIAL INTELLIGENCE APPLICATIONS

DEAL TO CREATE ADDITIONAL VALUE THROUGH SUBSIDIARY TO ADVANCE ARTIFICIAL INTELLIGENCE STRATEGY WITHOUT DILUTION TO BIOSIG TECHNOLOGIES SHAREHOLDERS

Westport, CT, July 25, 2023 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the completion of a seed funding round raising $2.2 million for BioSig AI Sciences, Inc. (“BAIS”), a subsidiary of the Company. BAIS intends to join BioSig’s world class technology team with external partners and collaborators to advance the research and development of an artificial intelligence (“AI”) medical device platform.

“The integration of AI and machine learning in electrophysiology devices is powering substantial expected growth for this market, and we intend to be a leader in developing applications of these technologies,” said Ken Londoner, Chairman, CEO and Founder of BioSig. “Our current platform and relationships have created interest and excitement and our development team are making demonstrations for early adopters” added Londoner.

BioSig and Reified Labs’ initial AI collaboration, which began in 2019, has resulted in multiple patent applications to date and a research publication on AI-enhanced electrocardiogram lead placement mapping. The renewed collaboration, BAIS, is also looking into the application of Chat-GPT like large language models and how they apply to helping our hospital partners leverage such technology to solve the myriad of challenges they currently face.

According to Data Bridge Market Research, the market for artificial intelligence in healthcare, estimated at $9.6 billion in 2022, is expected to reach $272.9 billion by 2030, at a CAGR of 51.9% during the forecast period.1 

About BAIS
BAIS, a majority-owned Delaware C Corporation subsidiary of BioSig, is developing AI solutions for the hospital marketplace utilizing structured, semi-structured, and unstructured data.

Clinical data acquired by the PURE EP™ System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. I want to note that BSGM has a long-term relationship with the Mayo Clinic in the development of the PURE EP™ System.

In February of 2023, Ascendiant Capital Markets’ analyst, Edward Woo, tagged BSGM with a $5.00 target.

Here’s some key highlights from the report:

Focused on PURE EP: The company has developed the PURE EP system whose enhanced signal acquisition, digital signal processing, and analysis provides key data used during ablation of cardiac arrhythmias. The PURE EP System is a FDA 510(k) cleared (in August 2018) non-invasive class II device.

Targeting heart disease: In the U.S., heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups, contributing to about 20 – 25% of deaths in the U.S. every year. Every 40 seconds, someone in the U.S. has a heart attack. Arrhythmia is a leading condition and contributing cause for heart disease.

PURE EP system: The PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP (Electrophysiology) System is designed to provide essential diagnostic signals during all types of cardiac catheter ablations (a procedure that involves delivery of energy through the tip of a catheter to correct heart rhythm arrhythmias). PURE EP is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials.

PURE EP benefits: PURE EP’s features may allow physicians to better determine precise ablation targets, strategy, and end point of procedures with the objective of reducing the need for patients to undergo multiple procedures, and to allow for less experienced EP physicians to perform more complex procedures. It is estimated that over half of cardiac ablation procedures are not successful (requires additional ablation procedures).

3,000 procedures and growing: To date, more than 3,000 patient procedures have been conducted with the PURE EP System by more than 80 electrophysiologists across 21 different clinical sites in the U.S. The PURE EP System is currently in national commercial launch in the U.S. at healthcare systems such as Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute.

Market opp’s: According to Health Research International, it is estimated that there are 8,163 global EP lab rooms (with an estimated 3,500 in the U.S.) performing catheter ablations. The rapidly growing EP market is projected to reach $16Bn by 2028 (+11.2% annual growth rate).

However, challenges exist: BioSig operates in a highly competitive environment and competes against a wide range of other technologies. There is the chance that competing technologies may challenge BioSig technologies or that existing standard of care methods remains the industry standard.

NEUROCLEAR

NOVEL ENG PLATFORM TECHNOLOGY

Our technology aims to address technological deficiencies present in the current electroneurogram recording systems through high-speed recording of biomedical signals, the ability to preserve valuable clinical information and optimization of therapy delivery through closed feedback loop.

Our first product focuses on improving safety and efficacy of renal denervation procedures.

INTRODUCING N-SENSE

  • Multi-channel hardware designed to sense & stimulate nerves.
  • Simultaneous stimulation and measure for optimal closed loop feedback system.
  • Aid in targeting nerve location.
  • Algorithms tailored to specific applications.
  • Assess nerve for hyperactivity.
  • Catheter-agnostic interface.

PARTNERSHIPS

We have partnerships with some of the most distinguished organizations and experts in the fields of electrophysiology, intellectual property (IP) strategy, and technology development.

In 2017 we signed a ground-breaking 10-year strategic collaboration with experts at Mayo Clinic to both develop advanced clinical features of the PURE EP™ System and explore new disease areas and applications. We expect our collaboration to result in joint patent filings and licensing opportunities. Our research program with Mayo Clinic is run under the leadership of Samuel J. Asirvatham, M.D., Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory.

We have worked closely with leading patent experts to develop a robust IP strategy. Our IP strategic advisor – Sherpa Technology Group (STG) – is one of the best in the field, working at the intersection of business, technology, and intellectual property. Our patent attorneys, Sterne, Kessler, Goldstein & Fox, are equally distinguished and have been on the cutting edge of IP law for four decades.

We also have a technology development partnership with Plexus Corp. [Nasdaq: PLXS]. Their engineering and manufacturing capabilities and outstanding expertise in building complex medical devices make Plexus a foundational cornerstone to support BioSig’s growth objectives now and well into the future.

Mayo Clinic
Sherpa Technology Group
Sterne, Kessler, Goldstein & Fox
Plexus Corp.

KEY GROWTH DRIVERS

  1. 1)  Advanced Technology — The non-invasive PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology EP procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. The PURE EP System aims to minimize noise and artifacts, and acquire high- fidelity cardiac signals. Improving cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and ablation procedures.
  2. 2)  Market Opportunity — 2019 DRG Medtech 360 Report states the global EP device market is expected to exceed more than US $10.1 billion by 2024 and is growing at a compound annual growth rate (CAGR) of 11.3%. The Company also operates within the rapidly emerging field of bioelectronic medicine, estimated at $25.11 billion in 2020 with projected annual growth of 10.27%.
  3. 3)  KOL Support — PURE EP has been used and valued by many of the industry’s leading electrophysiology physicians, including Dr. Andrea Natale of Texas Cardiac Arrhythmia Institute, and Dr. G. Joseph Gallinghouse. The Company achieved proof of concept validation through UCLA, and has performed numerous pre-clinical studies at Mayo Clinic, MN under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic’s Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory.

BIOELECTRONIC MEDICINE

Bioelectronic medicine is a rapidly growing field of healthcare that explores how targeted electrical signals can harness the body’s natural mechanisms to diagnose and treat a range of diseases. The field represents not just a narrow category of medical devices, but an entire approach to detecting and treating disease – using electrical pulses and the body’s own mechanisms as an adjunct or alternative to drugs and medical procedures.

BioSig Announces Successful First-In-Human Use of PURE EP System

Bioelectronic medicine applications aim to deliver treatment breakthroughs for many diseases that currently have a high level of unmet need. Researchers and innovators are exploring the field’s applications across various disease areas and disciplines, including neurology, auto-immune diseases, diabetes, arthritis, hypertension, pain management, cancer, and others. This wide range of applications sets bioelectronic medicine apart and indicates its immense potential.

We know we’re not alone in embracing a future with bioelectronic medicine. The field is making rapid strides, but this is just the beginning of what’s possible. That’s why we helped create the Alliance for Advancing Bioelectronic Medicine, an independent network of professionals dedicated to innovation at the intersection of healthcare and technology. We strive to develop this community with a common goal of realizing the field’s full potential.

Bioelectronic medicine is already a diverse, $20 billion market. It includes both familiar devices, such as pacemakers, as well as emerging technologies, such as vagus nerve stimulators and implantable neurostimulators. These exciting new segments are proliferating and attracting interest and investment from major players in technology and healthcare, such as Verily Life Sciences, Medtronic, and Johnson & Johnson.

As the field continues to develop, we believe our unique technology can play a critical enabling role. By providing more precise biomedical signals, our advanced signal processing capabilities can help clinicians better understand and change patterns to treat, or even prevent diseases.

NEWS

BIOSIG’S NEW PURE EP™ SUBSCRIPTION MODEL ADOPTED BY MAYO CLINIC-PHOENIX FOR WORLD-CLASS CARDIAC CARE

November 2, 2023

BIOSIG ADDS FIVE NEW PATENT AWARDS TO 100+ TOTAL PATENT PORTFOLIO COVERING DIGITAL SIGNAL PROCESSING TECHNOLOGY AND AI

November 1, 2023

BIOSIG AI SCIENCES ACHIEVES INFRASTRUCTURE AND TECHNOLOGY PROGRESS IN DEVELOPMENT OF GENERATIVE AI PLATFORM FOR HOSPITALS

August 24, 2023

BIOSIG INTRODUCES NEW SUBSCRIPTION MODEL FOR PURE EP™ PLATFORM, OFFERING QUICKER ACCESS TO LATEST FEATURES, CUSTOMIZATIONS

August 23, 2023

BIOSIG’S PURE EP™ PLATFORM DEBUTS NEW AUTOMATED FEATURES IN FIRST PATIENT CASES

August 22, 2023

BIOSIG AI SCIENCES RECEIVES $2.2 MILLION IN SEED FUNDING TO ADVANCE DEVELOPMENT OF ARTIFICIAL INTELLIGENCE APPLICATIONS

July 25, 2023

BIOSIG AI SCIENCES SELECTED FOR NVIDIA INCEPTION PARTNERSHIP PROGRAM TO SUPPORT R&D COLLABORATION ON AI MEDICAL DEVICE PLATFORM FOR HOSPITALS

July 20, 2023

BIOSIG JOINS WEBULL CORPORATE CONNECT

June 29, 2023

BIOSIG ADVANCES COLLABORATION ON MACHINE LEARNING AND ARTIFICIAL INTELLIGENCE SOLUTIONS FOR HEALTHCARE

June 27, 2023

NEW DATA AT HEART RHYTHM 2023 SUGGESTS THAT UNIPOLAR SIGNALS MAY BE USED FOR A MORE PRECISE, ACCURATE APPROACH TO TREATING ARRHYTHMIAS

May 19, 2023

BIOSIG TO HIGHLIGHT NEW DATA FROM THE PURE EP™ PLATFORM AT HEART RHYTHM 2023

May 3, 2023

BIOSIG ANNOUNCES NEW ADVISORY BOARD MEMBER EDWIN WANG

March 27, 2023

BIOSIG ANNOUNCES NEW ADVISORY BOARD MEMBER LORRAINE SPURGE

March 24, 2023

BIOSIG CONFIRMS NO EXPOSURE TO SILICON VALLEY BANK

March 13, 2023

BIOSIG REGAINS COMPLIANCE WITH ALL NASDAQ LISTING STANDARDS

February 22, 2023

BIOSIG AWARDED US PATENT CLAIMS FOR ITS UNIVERSAL NOTCH FILTER TECHNOLOGY

February 17, 2023

BIOSIG APPOINTS FORMER QORVO CFO AS SUCCESSOR TO STEVE CHAUSSY

February 7, 2023

BIOSIG ISSUES SHAREHOLDER UPDATE TO HIGHLIGHT RECENT ACHIEVEMENTS AND ONGOING DEVELOPMENTS

January 19, 2023

BIOSIG EXECUTES AGREEMENT WITH BELLIN HEALTH FOR THE ACQUISITION OF ITS PURE EP™ TECHNOLOGY

January 10, 2023

MANAGEMENT

Kenneth L. Londoner, MBA

KENNETH L. LONDONER, MBA

Founder, Chief Executive Officer, Chairman, and Director

Mr. Londoner is a capital markets and capital architecture expert and a senior life science executive. Having started his career as a research analyst for J. & W. Seligman & Co., Inc., a leading institutional money management firm in New York City, NY, he quickly found himself at the forefront of the biotech industry in the early 1990s, leading him to manage $3.5 billion in mutual and pension funds and international assets.

His passion for medical innovation led him to co-found, govern and bring to the public market several life science companies, including BioSig Technologies, Inc. [NASDAQ: BSGM]. Working in close collaboration with key opinion leaders in electrophysiology, BioSig aims to improve the outcomes of cardiac ablations for the treatment of arrhythmias through novel technological solutions developed by the company and further apply its core competency in advanced biomedical signal processing and analysis to other areas of medicine.

His prior experience in recognizing the early potential of biotech led Londoner to for the Alliance for Advancing Bioelectronic Medicine, an independent non-profit network of professionals dedicated to innovation at the intersection of healthcare and technology. The Alliance aims to increase awareness of bioelectronic medicine and build a platform for collaboration among stakeholders. Over the last decade, Londoner formed top-level relationships with several medical centers of excellence such as Mayo Clinic, NYU Langone Hospital, and UCLA, as well as other stakeholders, including investment communities, intellectual property experts, and supply chain partners.

Mr. Londoner earned his BA in Economics from Lafayette College in 1989, and his Master of Business Administration in Management and Finance from New York University in 1994. Between 1999-2002, he served as an adjunct professor at the Columbia Business School. Additionally, in 2015, Mr. Londoner founded the Immersive Internship Program at Lafayette College.

Steve Buhaly

STEVE BUHALY

Chief Financial Officer

Mr. Buhaly has over 15 years of CFO experience at three public U.S. companies. In 2007, he served as CFO to TriQuint Semiconductor who merged with RF Micro Devices, Inc. in a $4 billion merger agreement to form Qorvo in 2015. A world leader in innovative RF and power technologies, Qorvo grew into an $11 billion market capitalization during Mr. Buhaly’s tenure. Prior to TriQuint, Mr. Buhaly served as CFO of Longview Fibre where he played a key role in executing the $2.3 billion sale of the company. Earlier in his career, he held both chief operating officer and chief financial officer roles with electronic display company, Planar Systems.

Throughout his career, Mr. Buhaly has developed a strong cross-functional background in corporate finance, accounting, tax, IT, law, and investor relations. Having co-led strategic transactions resulting in over $2 billion in M&A transactions, he has helped companies raise $1 billion in the debt markets and was recognized for his leadership during TriQuint’s massive growth trajectory. Since 2018, Mr. Buhaly has served as an advisor to multiple early-stage and small businesses and currently consults for cancer treatment innovator, UbiVac.

Mr. Buhaly holds an MBA from the University of Washington.

Gray Fleming

GRAY FLEMING

Chief Commercial Officer

Mr. Fleming brings to the Company over 20 years in the healthcare industry, including 17 years at Abbott Laboratories and St. Jude Medical. During his tenure with Abbott, Mr. Fleming held several commercial leadership positions, including Vice President of Cardiac Sales, when he led sales and customer relationship management activities in some of the most significant strategic areas of focus. Mr. Fleming’s experience in delivering high-performing sales management initiatives led to substantial revenue growth with several key accomplishments, including the successful contracting of multiple leading IDN and GPO organizations. These initiatives resulted in some of the largest market share gains in the company’s history while also delivering substantial overhauls of historically underperforming regions throughout the Central Time Zone. Most recently, Mr. Fleming held the position of Chief Commercial Officer at Carecubes, a company created to provide a temporary and scalable negative pressure isolation technology solution based upon original joint request from the Defense Advanced Research Projects Agency (DARPA) and Centers for Disease Control and Prevention (CDC). Mr. Fleming holds a Bachelor of Business Administration degree with a Major in Marketing from Stephen F. Austin State University in Texas and a certificate in Leadership in Excellence and Development (LEAD) Program from the University of Texas.

John Sieckhaus

JOHN SIECKHAUS

Chief Operating Officer

Mr. Sieckhaus brings to the Company 30 years in the healthcare industry, including 21 years at St. Jude Medical and Abbott Laboratories [NYSE: ABT]. During his tenure with St. Jude Medical, Mr. Sieckhaus held commercial leadership positions of rising responsibility, including U.S. National Sales Leader, Senior Vice President & General Manager when he led sales and customer relationship management activities in the United States across all cardiovascular product lines.   Mr. Sieckhaus’s experience in building and leading high-performance teams, in addition to integrating multiple new and novel technologies and introducing them commercially, led to significant revenue growth for St. Jude Medical over his career. Most recently, Mr. Sieckhaus held the position of Vice President – Field Clinical Affairs for Abbott for the United States and CALA, where he created a world-class field clinical and monitoring team to support clinical trials across multiple business units within Abbott’s Cardiovascular portfolio. Mr. Sieckhaus holds a Bachelor of Science degree in Biomedical Engineering from Johns Hopkins University.

Brenda Castrodad

BRENDA CASTRODAD

Vice President, Human Resources

A seasoned executive, Ms. Castrodad brings a wealth of experience in leading organizational development in start-ups and Fortune 500 companies within the life sciences sector. Most recently, Ms. Castrodad led the HR department at TissueTech, Inc., a Miami, FL-based biotech leader in regenerative amniotic tissue-based products, where she was responsible for transformation and automation of the company’s HR practices, talent planning, and team building. Prior to TissueTech, Inc., Ms. Castrodad spent six years at HeartWare, Inc., a heart failure medtech company acquired by Medtronic [NYSE:MDT] in 2016 for $1.1 billion. By optimizing the internal talent acquisition function and aligning business practices, Ms. Castrodad helped grow the organization from approx. 80 to 500+ staff which achieved approx. $250 million in revenues before the acquisition. Earlier in her career, Ms. Castrodad spent 16 years at Schering-Plough Corp, a pharmaceutical company acquired in 2009 for $41.1 billion by Merck & Co. [NYSE:MRK]. Ms. Castrodad holds a Master’s Degree in Public Administration and a Bachelor’s Degree in Social Sciences – Human Welfare from the University of Puerto Rico and a Labor Relations Certificate from the University of Michigan.

Andrew Ballou

ANDREW BALLOU

Vice President, Investor Relations

Mr. Ballou brings to BioSig over 25 years of experience in capital markets, including institutional equity sales and research analysis. Most recently, Mr. Ballou served as Managing Director, Head of Institutional Equity Sales at Janney Montgomery Scott LLC., a role in which he oversaw key accounts, including large multi-manager hedge funds, mutual funds and dedicated sector funds. Prior to that role Mr. Ballou managed selected key account coverage at RBC Capital Markets, including Millennium Partners, Soros Fund Management, SIR Capital, Columbia Threadneedle, Two Sigma Investments and Times Square Capital Management. During the course of his career Mr. Ballou analyzed various private and public companies in healthcare, media and retail sectors. Mr. Ballou graduated from Hampden-Sydney College, Virginia, with a Bachelor of Arts in English.

Katie Freshwater

KATIE FRESHWATER

Vice President, Marketing

Ms. Freshwater brings over 20 years of sales and marketing experience in healthcare and technology, including senior positions at several leading medtech companies such as Cardinal Health, Medtronic, and Kimberly-Clark Healthcare.  During her tenure at Cardinal Health, Ms. Freshwater served as Senior Director of Digital Marketing, e-Commerce, and Brand where she oversaw the development of marketing tech strategy and a team of 20+ digital marketers, content creators, and paid media strategists. More recently, Ms. Freshwater founded FRESH20 Consulting, where she has served as Senior Consultant providing independent marketing services and modern sales solutions for businesses ranging from early state startup-ups to large corporations.

At BioSig, Ms. Freshwater will work directly with all facets of the company on development, implementation, and management of the Company’s strategic and tactical marketing activities. She is responsible for developing and delivering a fully integrated marketing strategy, to include MarTech and MarCom functions. In addition, Mrs. Freshwater will support the Company’s brand visibility across print and digital media through best-in-class tailored approaches that drive sustainable growth for the business.

Ms. Freshwater holds a bachelor’s degree in business administration from the University of Denver and an MBA from Baylor University.

Zachary Koch, CCDS, CEPS

ZACHARY KOCH, CCDS, CEPS

Principal Advisor, Product Development

Zachary Koch brings over 20 years of experience in clinical strategy and sales in electrophysiology and cardiovascular devices. Mr. Koch joins BioSig’s leadership following a 16-year tenure at Abbott and St. Jude Medical, where he held numerous positions across the company’s clinical, sales, training, and commercial teams. Mr. Koch has personally supported over 5000 cardiac mapping procedures, and has created and lead several advanced training and education initiatives for St Jude Medical and Abbott EP. More recently, within his role as Manager of Strategic EP Clinical Development, Mr. Koch successfully founded and launched the Key Accounts Organization for Abbott EP and led the business and clinical strategy across nine National Key Accounts. These efforts generated a 20% increase in EP case volume and revenue for the company. He also founded the AAA advanced training program that led to a significant improvement of clinical support with the Key Accounts Organization.  He has been recognized for his sales and business delivery as a three-time recipient of Abbott’s Field Service Award, an honor bestowed upon the top clinical specialists in the US sales division.  He is also a certified electrophysiology and cardiac device specialist, a distinguished honor apportioned by the International Board of Heart Rhythm Examiners.

Mr. Koch served as a Hospital Corpsman in the United States Navy.  He provided infantry medical support for the Second Marine Division and the Executive Medical Team at the National Naval Medical Center in Washington DC. He holds a degree in Cardiovascular Technology from the Naval School of Health Sciences, where he graduated with honors and distinction.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWELVE THOUSAND USD BY SICA MEDIA LLC FOR A ONE DAY BSGM AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(NASDAQ: WLDS) Profile

Wearable Devices Ltd.

OUR NEW PROFILE IS:  (NASDAQ: WLDS)

THE ENTIRE FLOAT IS UNDER 8 MILL RIGHT NOW!!!

Wearable Devices Unveils New Gesture & Voice-Controlled Interface for its Mudra Band for Apple Watch

Wearable Devices Expands Mudra Licensing Program to Include Defense and Military Applications

Wearable Devices Entered an MOU with a Leading XR Smart Glasses OEM for its Mudra Licensing Program

READ THE INVESTOR PRESENTATION HERE

      _________________

Hello Everyone,

We want you to pull up WLDS right away.

WLDS is a growth company developing a non-invasive neural input interface in the form of a wrist wearable band for controlling digital devices using subtle finger movements. These digital devices include consumer electronics, smart watches, smartphones, AR glasses, VR headsets, televisions, PCs, laptop computers, drones, robots, etc.

Since our technology was introduced to the market in 2014, we have been working with both Business-to-Business (B2B) and Business to Consumer (B2C) customers as part of our push-pull strategy.

We are now in the transition phase from research and development to commercialization of our technology into B2B products. At the same time, we are in the final stage of manufacturing our first B2C consumer product, the “Mudra Band”, an aftermarket accessory band for the Apple Watch which allows touchless operation and control of the watch. Headquartered in Israel, the company was founded in March 2014 by Asher Dahan, Guy Wagner and Leeor Langer, with renowned expertise in the fields of analog sensors, signal processing, deep learning and machine learning algorithms, software, and human-computer interaction.

Year-To-Date Operational Highlights

  • Announced preorder availability for flagship consumer product, Mudra Band forApple Watch
  • Commenced commercial manufacturing of Mudra Band for Apple Watch
  • Launched AI-based Air-Touch functionality for Android
  • Filed patent application with United States Patent and Trademark Office for expandedAI-based immersion technology
  • Strengthened leadership team with the addition of Tamar Fleisher as Chief OperatingOfficer and Pankaj Kedia to advisory board
  • Announced Mudra Band compatibility with B2B and B2C smart glasses brands
  • Enabled new user experience for mobile gaming
  • Showcased Mudra technology at numerous industry conferences around the globeSubsequent to the second quarter of 2023:
  • Completed first manufacturing batch of the Mudra Band for Apple Watch; expects tobegin shipments in coming weeks

WEARABLE DEVICES UNVEILS NEW GESTURE & VOICE-CONTROLLED INTERFACE FOR ITS MUDRA BAND FOR APPLE WATCH

The integration allows users to harness both voice commands and gestures to control digital devices without the need for physical touch.

YOKNEAM ILLIT, ISRAEL, Oct. 26, 2023 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (AI) powered touchless sensing wearables, announced today the integration of a new gesture and voice controlled interface for its Mudra Band for Apple Watch and AirTouch technology that leverages Apple’s AI-based digital assistant, Siri.

The new integration provides users with an enhanced interactive experience, enabling them to use a combination of voice commands and natural gestures and movements to control devices, without the need for physical touch. The combination of voice assistance and AirTouch technology allows users to switch between devices using voice, then utilize AirTouch gesture detection capabilities to navigate and fine tune preferences such as volume, brightness, and more.

Guy Wagner, Chief Scientist Officer and Co-Founder of Wearable Devices, commented, “With natural human communication being a combination of speech and gestures, an interface that utilizes both voice and gesture recognition as an input method is an essential integration for our technology. To date, we’ve been able to develop a revolutionary product that allows for natural and touchless interaction with connected devices using AI-powered sensors to interpret subtle finger and hand movements. With the integration of speech, we are greatly expanding the scope and capabilities of our technology by adding an entirely new input method that leverages the virtual assistant AI technology found in many of our connected devices, making our products, and other connected products, more intuitive and easier to use than ever before.

WEARABLE DEVICES EXPANDS MUDRA LICENSING PROGRAM TO INCLUDE DEFENSE AND MILITARY APPLICATIONS

The Company has been approached by global defense and military organizations interested in incorporating advanced technologies into their operations

YOKNEAM ILLIT, ISRAEL, Oct. 23, 2023 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (AI)-powered touchless sensing wearables, today announced the expansion of its Mudra gesture technology licensing program (the “Licensing Program”) to include defense and military applications, in response to the increasing demand within this sector.

The Company has already received requests for quotes from leading global defense and homeland security companies seeking to evaluate Mudra technology for potential integration into their own products and operations. With the control of defense technology increasingly shifting to ground and field operators, Mudra gesture technology offers customized, easy-to-use, discreet solutions that can maximize efficiency and minimize margin for error in environments where these are of the utmost importance.

The Licensing Program provides original equipment manufacturers with the right to customize a reference design version of the Company’s award-winning Mudra gesture technology to meet the specific needs of their business. The Company’s proprietary technology is at the forefront of gesture recognition, using AI-based touchless sensing wearables to control devices with hand gestures. Through the Licensing Program, Wearable Devices is positioned to significantly expand its addressable market by enabling businesses to develop their own co-branded touchless control products.

Asher Dahan, CEO of Wearable Devices, commented, “Our expansion into the defense and military sector reflects the expanding demand for our technology and the variety of applications our technology can enhance and support. We’ve been approached by several leading defense and homeland security companies that have recognized the potential of our Mudra gesture technology in their products and operations. As defense technology becomes an imperative part of the defense industry, our customizable and user-friendly gesture solutions are ideally suited for the direction in which this market is headed.”

WEARABLE DEVICES ENTERED AN MOU WITH A LEADING XR SMART GLASSES OEM FOR ITS MUDRA LICENSING PROGRAM

YOKNEAM ILLIT, ISRAEL, Oct. 02, 2023 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the “Company”), a technology growth company specializing in AI-powered touchless sensing wearables, today announced the signing of a non-binding Memorandum of Understanding (“MOU”) under its newly launched Mudra licensing program. The MOU has been signed with a leading Chinese original equipment manufacturer (“OEM”) of extended reality (“XR”) smart glasses.

Under the terms of the MOU, the XR smart glasses OEM will explore deploying Wearable Devices’ touchless technology into its own product suite. As defined in the MOU, upon successful evaluation, the parties would enter into a commercial license agreement.

This MOU is a testament to Wearable Devices’ commitment to expanding its cutting-edge technology through strategic partnerships, and it marks a significant milestone in the Company’s journey toward defining the future of human-device interaction.

Wearable Devices recently announced its new licensing program for the B2B market, the ‘Mudra Licensing’. With the new program, the Company will provide a royalty-based license agreement, where OEMs =will have the right to manufacture by themselves a custom reference design version combined with the Company’s touchless control technology.

“We’re thrilled to partner with one of the major players in the XR market,” said Asher Dahan, Chief Executive Officer of Wearable Devices. This collaboration could significantly advance the capabilities of XR smart glasses and headsets as well, offering users a more intuitive and immersive experience.”

NEWS

Wearable Devices Unveils New Gesture & Voice-Controlled Interface for its Mudra Band for Apple Watch
aria-label.authors-picture

Wearable Devices

PRESS RELEASES

Wearable Devices Unveils New Gesture & Voice-Controlled Interface for its Mudra Band for Apple Watch

The integration allows users to harness both voice commands and gestures to control digital devices without the need for physical touch….

Wearable Devices Announces Receipt of Nasdaq Minimum Bid Price Notification
aria-label.authors-picture

Wearable Devices

PRESS RELEASES

Wearable Devices Announces Receipt of Nasdaq Minimum Bid Price Notification

YOKNEAM ILLIT, Oct. 24, 2023 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the “Company”) , a…

Wearable Devices Expands Mudra Licensing Program to Include Defense and Military Applications
aria-label.authors-picture

Wearable Devices

PRESS RELEASES

Wearable Devices Expands Mudra Licensing Program to Include Defense and Military Applications

The Company has been approached by global defense and military organizations interested in incorporating advanced technologies into their…

Wearable Devices Expands its Impact within the Industry’s XR Landscape by Joining the OpenXR Voting
aria-label.authors-picture

Wearable Devices

PRESS RELEASES

Wearable Devices Expands its Impact within the Industry’s XR Landscape by Joining the OpenXR Voting

Wearable Devices will join industry standard voting committee of OpenXR, which includes among others, prominent players such as Apple,…

Wearable Devices Joins Khronos Group As A Voting Right Member To Help Drive The OpenXR Industry Stan
aria-label.authors-picture

Wearable Devices

PRESS RELEASES

Wearable Devices Joins Khronos Group As A Voting Right Member To Help Drive The OpenXR Industry Stan

Wearable Devices’ Co-Founder: “We’re excited to join Khronos Group and help define the future of the OpenXR Standards” YOKNEAM ILLIT,…

Wearable Devices Entered an MOU with a Leading XR Smart Glasses OEM for its Mudra Licensing Program
aria-label.authors-picture

Wearable Devices

PRESS RELEASES

Wearable Devices Entered an MOU with a Leading XR Smart Glasses OEM for its Mudra Licensing Program

YOKNEAM ILLIT, ISRAEL, Oct. 02, 2023 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the…

Wearable Devices to Enhance Apple Watch Series 9 New ‘DoubleTap’ Feature With its Mudra Band Touchle
aria-label.authors-picture

Wearable Devices

PRESS RELEASES

Wearable Devices to Enhance Apple Watch Series 9 New ‘DoubleTap’ Feature With its Mudra Band Touchle

Using the Mudra Band spatial gestures in tandem with the Apple Watch Double Tap gesture should allow for full touchless control across…

Wearable Devices’ Mudra Band Enables Full Touchless Control of Apple Product Ecosystem
aria-label.authors-picture

Wearable Devices

PRESS RELEASES

Wearable Devices’ Mudra Band Enables Full Touchless Control of Apple Product Ecosystem

Using the Mudra Band Air-Touch feature in tandem with the Apple Watch AssistiveTouch touchless gesture control feature allows for full…

Apple Watch Users Received The First Wearable Devices Mudra Bands
aria-label.authors-picture

Wearable Devices

PRESS RELEASES

Apple Watch Users Received The First Wearable Devices Mudra Bands

The Company delivered its award winning Mudra Band product to first customers, allowing them to control their Apple ecosystem devices…

MANAGEMENT  

Asher Dahan

CEO & Co-Founder Director

Project execution expert. Talent in business leading and strategic planning. Manager and team leader. High expertise in major corporate decisions, experience managing the overall operations and resources of the Company.

Guy Wagner

Company President & Chief Scientist, Co-Founder Director

Hardware expert and main inventor. Multi- disciplinary expertise in board design, biomedical signal processing, embedded programming and sensor design.

Leeor Langer

CTO & Co-Founder

Algorithms expert. Machine learning, and signal / image processing developer. Lead algorithms engineer in industry and academia. Wrote several papers and articles.

Eli Bachar

Director

Director since 2016. Serial investor experience served as director in multiple companies (Xjet3D , 6 Over 6 Vision Ltd., GetSat Ltd., Silentium Ltd., Cupixel Ltd.)

Barry Kaplan

EVP US operation & Director

Director since 2018. From 2012 to 2021, Chief of Operations at Stuhrling Original Group of companies. From 2009 to 2014 founded and worked as CEO at KIVA watch.
He was Chief Executive Officer and Chief Designer of Alexander Watch LLC from 2014 to 2017

Alon Mualem

CFO

An experienced CFO with diverse experience in multinational hi-tech, communication and industrial companies, both public and private companies. Previously served as the CFO of Eltek (NASDAQ:ELTEK), as the CFO of Mer Telemanagement Solutions Ltd., a company traded on NASDAQ. and as the CFO of Xfone Inc. and Xfone 018 Ltd.

Offir Remez

EVP of Business development and sales

A serial entrepreneur and a senior business executive with a proven track record among OEMs and international corporations. Co-founder and former President and VP BD of LucidLogix (acq. Google). Active board member and VP BD at Adshir (acq. Snap)Adv. board member at Play-Cast (acq. GameFly), 3DV (acq. Microsoft), North-Bit (acq. MagicLeap), Giraffic (acq. Roku)Co-founder & CEO of Enbaya

Shmuel Barel

CMO

International B2B and B2C marketing and sales expert on both Industrial and consumer products and services.

Highly experienced in business and marketing strategy, branding, digital advertising, media planning, multi-channel analytics, and customer support.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY AMPLIFYIR INC FOR A ONE DAY WLDS AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.